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DEVELOPMENT OF LC-MS/MS METHODS FOR QUANTITATIVE 
ANALYSIS OF PLANT-DERIVED ANTICANCER AGENT AND 
SYNTHETIC ESTROGEN IN COMPLEX MATRICES  
SIMULI LINDAH WABUYELE  
ABSTRACT 
Quantitative methods of analysis play an important role in early stages of drug 
discovery and clinical development, as well as, biomonitoring studies of human exposure 
to endocrine disrupting chemicals (EDCs). It is significant to develop quantitative 
methods that are highly sensitive, selective and accurate for potential anticancer drugs 
and EDCs (or their metabolites) in complex matrices considering the fact that; 1) some 
anticancer agents have a low therapeutic index and have failed in the clinical trials, and 2) 
the effects of some EDC have been found to occur at very low concentrations.  Therefore, 
such quantitative methods could help predict the absorption, distribution, metabolism and 
elimination (ADME) of the anticancer agents, and provide a better understanding of the 
efficacy of the drug and levels of toxicity. In addition, insight on the biotransformation 
and toxicokinetics of EDCs could be obtained for better assessment of the exposure 
levels and dosage effect.
Currently, the most powerful technique for quantitative analysis is liquid 
chromatography (LC) method of separation coupled to tandem mass spectrometry (ESI-
ix 
MS/MS). In this dissertation, a brief overview of the methodology, instrumentation, 
samples preparation techniques and essential parameters for bioanalytical method 
validation will be discussed, as well as, the work flow of liquid chromatography tandem 
mass spectrometry (LC-MS/MS) method development. LC-MS/MS was exploited for 
quantitative analysis of (-)-Securinine (SE), a plant-derived anticancer agent and 
Bisphenol A (BPA), a synthetic estrogen. 
 In order to facilitate the pharmaceutical development of SE natural products, i.e., 
ensure quality, efficacy and safety; a sample preparation method was developed to isolate 
SE from its natural source; Securinega suffruticosa plant and an LC-MS/MS method was 
developed and validated to quantify the SE in  raw plant material.  The method developed 
was applied to the quantitative analysis of the distribution and levels of SE in different 
parts of S. suffruticosa plant (i.e., leaves, roots, stems, bark and branches). 
Furthermore, in order to support the pharmacological studies of SE as a potential 
anticancer drug, an LC-MS/MS method was developed and validated for quantitative 
determination of SE in mouse plasma and was applied to the measurement of SE 
concentrations in  a mouse study. 
Lastly, in order assess human exposure to chemicals that mimic endogenous 
hormonal action and interfere with the endocrine function (i.e., synthetic estrogens) 
highly sensitive and accurate techniques are crucial. Due to the prevalence of BPA in 
laboratory environment and reagents, a metabolite of BPA i.e., Bisphenol A β-D-
glucuronide (BPA-G) was used as a urinary biomarker to assess human exposure to BPA. 
A stable isotope dilution (SID)-LC-MS/MS method was developed, validated and 
successfully applied to the measurements of BPA-G in 40 patients’ urine samples. 
x 
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CHAPTER I 
INTRODUCTION TO QUANTITATIVE LC-MS/MS METHOD DEVELOPMENT 
FOR PLANT-DERIVED ANTICANCER AGENT AND SYNTHETIC ESTROGEN  
1.1 General introduction  
The early stages of drug discovery encompass the identification of new drugs that 
target molecular and biological pathways that seem to play a role in various diseases 
including cancer. This discovery is then followed by isolation , characterization and then 
clinical development i.e., preclinical studies, clinical trials and pharmaceutical production
(Figure1 ) [1]. The success of these early stages of drug discovery and development, as 
well as, biomonitoring studies (i.e., determination of internal dose) of human exposure to 
endocrine disrupting chemicals EDCs depends on various analytical technologies, such
as, qualitative and quantitative methods of analysis, among other disciples of science.
2An efficient and high-throughput approach is required in order to characterize 
drug “lead” compounds and specific EDCs, as well as, measure their concentrations in
biological matrices during the pre-clinical developments and biomonitoring studies. This 
enables the prediction of absorption, distribution, metabolism, and elimination (ADME) 
of the drug over time throughout the body. Moreover, these allows one to monitor how 
fast the drug starts to act, the effect and duration of the drug which ultimately affects the 
administration i.e., the amount and intervals of dosing [2]. Hence, provide a better 
understanding of the efficacy and toxicity levels; since new drugs have failed in the 
clinical trials not only due to unpredicted toxicity but also metabolism problems [3, 4]. In 
addition, since the effects of some EDCs have been found to occur at very low 
concentrations; the quantitative determination of internal levels and understanding the 
biotransformation and toxicokinetics of the EDCs is imperative to provide a better 
assessment of the exposure levels and dosage effect [5-7]. 
Significant progress over the recent years in liquid chromatography separation, 
mass spectrometry detection, and sample pre-treatment techniques has facilitated 
bioanalytical method development and validation. Liquid chromatography tandem mass 
spectrometry (LC-MS/MS) has emerged as the most powerful technique capable to 
analyze unknown and structurally diverse molecules in complex matrices, with high 
performance, sensitivity and selectivity [1, 8]. In this work, LC-MS/MS methods were 
developed and validated to quantify (-)-Securinine (SE), a plant derived anticancer agent 
and Biphenol A (BPA), a synthetic estrogen also known as an endocrine disrupting 
compound. 
3 
Figure 1: Drug discovery and development process [9] 
4 
1.1.1 Natural products in cancer therapy 
Cancer is a group of diseases with characteristically abnormal growth of cells that 
rapidly divide and form tumors, some of which spread and invade (metastasize) other 
tissues and become life-threatening. It’s the second most common cause of death in the 
US, following heart disease[10] and has been estimated by the American Cancer Society 
that it’s responsible for at least 1 of every 4 deaths. In 2013, the total estimated cancer 
deaths in America is about 580,350 i.e., close to 1,600 people per day. As these numbers 
keep increasing with new cancers cases every year (i.e.,1,660,290 diagnosed)[10] there 
has been an increased demand on cancer research to prevent inhibit, delay or reverse the 
life threatening disease. 
Traditional cancer treatments including surgery, chemotherapy, and radiotherapy 
are commonly used but they are limited as single modalities [11]. Chemotherapy for 
example, is toxic to both cancer cells as well as the normal non-cancerous cells, whereas, 
radiotherapy kills the tumor cells as well as affects the nearby normal cells. Due to the 
limitation of tradition cancer treatment, other therapies including targeted therapies have 
emerged. In targeted therapy, specific chemotherapeutic agents; naturally occurring or 
synthetic chemicals, modulate specific signaling pathways involved in the carcinogenesis 
and  block the out of control growth and spread of cancer. This therapy has proved 
effective and has been used in together with traditional therapies as combination therapies 
for a higher efficacy and decreased cytotoxicity [12]. Therefore, to establish effective 
5cancer therapy, there is a need for discovery and development of new molecular targets 
for cancer prevention and therapy.  
 Natural products have been exploited as a source for new drug targets since 
ancient times [13-15]. It’s reported that over 60% of the anticancer drugs currently  
approved are obtained from natural sources including plants, marine organisms and 
micro-organisms [16]. Its been estimated that about  80% of  the people in developing 
countries take traditional medicine for their primarily health care  and about 85% of 
traditional medicine involves the use of plant extracts [9]. A majority of plants used for 
medicinal purposes, have been the primary source of chemotherapeutic agents and served 
as leads for the early drug discovery and development. In the US, a few plant-derived 
anti-cancer agents have been approved for use i.e., vinblastine (VLB), vincristine (VCR), 
etoposide (VM 26), teniposide (VP 16-213), vinorelbine (VRLB), vindesine (VDS), 
Paclitaxel (taxol®), docetaxel (Taxotere®), Topotecan and Irinotecan (CPT-11; 
Camptosar) [14, 17]. Besides being used to obtain the active compounds, natural plant 
products has been used the source of the starting drug for semi-synthesis  and as  models 
for new synthetic drugs [9].  
The development of novel chemotherapeutic agents from natural sources is faced 
with various challenges and has been constrained by the lack of sufficient plant resources, 
inability to access the pertinent sources as well as identification, isolation  and production 
of the active compound in large quantities necessary[14]. Despite the challenges faced, 
natural sources/products continue to significantly impact the development of new 
molecular targets for modern combination therapies to minimize or solve the problems 
inherent to the traditional cancer treatments. 
61.1.1.1 Plant-derived anticancer agents  
In this work, naturally occurring Securinega alkaloids will be discussed. These 
are a group of polycyclic compounds isolated from the plants of Securinega and 
Phyllanthus specie of Euphorbiaceae family. The four known alkaloids (Figure 2) from 
this class include; securinine, virosecurinine (viroSE), allosecurinine (alloSE) and 
viroallosecurinine (viroalloSE). Securinine has been found to be the major alkaloid in the 
leaves of Securinega suffruticosa and alloSE as the minor alkaloid and the roots of the 
plant contain securinine and alloSE as minor and major alkaloids respectively. On the 
hand, viroSE is the major and viroalloSE is the minor alkaloid from the leaves of 
Securinega virosa [18-23].
Securinine was the first member of these alkaloids to be isolated from its natural 
source i.e., Securinega suffruticosa a plant that is well distributed in north eastern parts of 
Asia and has been used in Chinese folk medicines [22]. (-)-Securinine (SE) exhibits a 
wider range of biological activities and recently it has been found to have potential 
clinical use as anticancer agent for acute myeloid leukemia (AML) and colon cancer [24-
26]. 
  In order to facilitate the pharmaceutical development and ensure quality efficacy 
and safety of SE natural products, a sample preparation method and an LC-MS/MS 
methods were developed to isolate SE from Securinega suffruticosa plant, and quantify 
the levels of accumulation in different parts of the plant (Chapter I). Also, to support the  
7Figure 2: The Securinega alkaloids 
8pharmacological studies of SE, an LC-MS/MS method was developed, validated and 
applied to the measurement of SE concentrations in a mouse study (Chapter II). 
1.1.2 Endocrine disrupting chemicals (EDCs) 
The human endocrine system (Figure 3) is know to controls various biological 
processes in the human body during the early stages of development (i.e., cell 
differentiation and organ formation), as well as, upon maturity. The endocrine glands are 
responsible for producing hormones involved in various signaling pathways for normal 
functioning of various tissues and organs [27]. 
 Endocrine disruptors are exogenous chemicals that act like hormones via binding 
to hormone-receptor protein complex (Figure 4) and disrupt hormonal action. These 
compounds interfere with the endocrine function consequently causing adverse 
physiological effects which could results in various cancers i.e. breast cancer, prostate 
cancer, and other reproductive disorders. EDCs are known to affect the hormonal action 
of estrogen, androgen, thyroid among other biological processes [27]. 
1.1.2.1 Synthetic estrogen  
Synthetic estrogens (i.e., xenoestrogens) are chemicals that enter the body and 
bind to estrogen receptor and mimic its actions. Examples include chemicals i.e., 
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Figure 3: Human endocrine system [27]. 
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Figure 4: Hormonal action via receptor binding [27].
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polychlorinated biphenyls (PCBs), biphenyl A (BPA) and phthalates [28]. In work, BPA 
will be discussed. 
BPA is used to make polycarbonate plastic and epoxy resins which are found in 
many consumer products i.e., food containers, water bottles, dental sealants, baby bottles 
and also, used as a linings / inner coating of food cans or beverages to prevent rusting 
[29, 30]. BPA is first synthesized via condensation (Figure 5) of two equivalents of 
phenol with acetone (thus the use of the suffix A in the name) then, BPA can react with 
phosgene or diphenyl carbonate to form polycarbonate polymers (Figure 6). However, 
when incomplete polymerization occurs or the ester linkages are subject to high 
temperature or exposed to acidic/basic conditions, BPA  leaches out into the food or 
beverages [31]. This frequently exposes humans to BPA which could result in adverse 
physiological effects [32-34]. 
BPA was discovered as a synthetic estrogen in 1930s [35]. The structure of BPA 
closely resembles that of estradiol,; the endogenous estrogen (Figure 7), in that, both 
compounds share the phenol groups, which has been reported to be the important site for 
receptor recognition [36]. Hence, BPA can bind to the estrogen receptor (ER) α and β, 
with 10 times higher affinity for ERβ and mimics its hormonal action [37, 38] acting as 
an endocrine disrupting compound. 
Initially, BPA was considered a weak environmental estrogen because of its 
relatively low affinity for the nuclear ERs compared with estradiol in some assays [39, 
40]. However, recently it’s been found that BPA can activate rapid cellular responses at 
very low concentrations; below the levels where BPA was initially expected to bind to  
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Figure 5: Synthesis of BPA 
http://en.m.wikipedia.org/wiki/Bisphenol_A
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Figure 6: Synthesis of polycarbonate plastic 
http://en.m.wikipedia.org/wiki/Bisphenol
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Figure 7: Chemical structure of BPA and endogenous estrogen 
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the receptor [41]. Also, animal studies suggest that BPA could cause effects in animal 
models at levels in the range of human exposure [31, 42-44]. 
Therefore, biomonitoring studies (i.e., assessment of internal dose) of human 
exposure to BPA require highly specific and accurate analytical methods of quantitation. 
In order to minimize BPA contamination, in this work, the metabolite of BPA i.e., 
bisphenol A β-D-glucuronide (BPA-G) was used as a urinary biomarker to assess human 
exposure to BPA. A stable isotope dilution (SID)-LC-MS/MS method was developed, 
validated and successfully applied to the measurements of BPA-G in 40 patients’ urine 
samples (Chapter IV). 
1.2 Quantitative methods of analysis 
Traditionally, quantitative analysis was performed using immunoassay methods 
i.e., radio-immunoassay (RIA), enzyme-multiplied immunoassays (EMIT) and 
fluorescence polarization immunoassay [FPIA]. Although, the estimate of the free drug 
concentration with these methods is comparable to LC; they tend to overestimate the 
values, due to non-specific binding of the antibody to the drugs. Also, the interferences 
from the biological matrices result in decreased accuracy of the assays, because they are 
not highly specific. 
 In addition, evaporative light scattering detection (ELSD), and chemiluminescent 
nitrogen detection (CLND) coupled to liquid chromatography (LC) has also been used for 
quantitative analysis. ELSD is a technique sensitive to mass of the analyte remaining 
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after solvent evaporation and is thus limited by the fact that volatile, low melting point 
compounds cannot be detected. CLND on the other hand depends on the number of 
nitrogen atoms in the sample, therefore, its nitrogen selective and could be limited by 
impurities and solvents that contain nitrogen [1]. These techniques with their limitations 
are not applicable for drug analysis on a large scale basis.  
Improvements have been made towards liquid chromatography coupled to 
ultraviolet (UV), fluorescence, electrochemical detection and gas chromatography (GC) 
coupled to mass spectrometry techniques. These methods have a better sensitivity, 
linearity, precision and could analyze small sample volumes simultaneously in bio-
matrices than the earlier methods and thus have become the  most commonly employed 
techniques. 
UV detects only molecules that are able to absorb UV light and the absorbed 
energy is proportional to the concentration of the compounds of interest at certain 
concentration ranges. It’s therefore not specific in that, various analogues of the 
compound of interest could also absorb in the same UV region. 
Electrochemical and fluorescence detection are more sensitive and  specific than 
UV , but are limited by the fact that they requires compounds that have electro-active 
groups or are fluorescent. Therefore, derivatization of the compounds will be required, 
which could alter the physical chemical properties of the drug analyzed and could also be 
time consuming. 
GC-MS on the other hand, couples the unsurpassed specificity of the MS to 
capillary GC for analysis of compounds of low polarity. However, some of this 
compounds despite their low polarity, they are too large to be analyzed without 
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decomposition. Moreover, many pharmaceutical drugs are polar, non-volatile and 
thermolabile, for this reason, they cannot be analyzed by this technique [45]. 
All the aforementioned methods are limited in their application to quantitative 
analysis; however, with further improvements in the areas of hyphenation (combination) 
of analytical techniques, liquid chromatography tandem mass spectrometry (LC-MS/MS) 
emerged as the most powerful method for the analysis of pharmaceutical compounds. 
Due to its unsurpassed capability of high through-put analysis, sensitivity and selectivity 
it has been used for identification of novel drug targets, chiral impurities, and degradation 
products/metabolites etc.[8] So far, it’s the unrivalled method for pharmaceutical drug 
and metabolite quantification. 
1.2.1 Liquid chromatography-mass spectrometry (LC-MS) 
1.2.1.1 Liquid chromatography (LC)  
LC is used to separate the analyte of interest from biological matrix components 
and complex mixtures. Also, it’s a way of introducing the analyte, into the MS for 
analysis, in solution. The LC system consist of the mobile phase (in the solvent 
reservoirs), binary pumps that keep the mobile phase flowing at a constant flow in the 
system, an autosampler for sample injection, a guard column to protect the column from 
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contamination, a column for separation and finally, a detector which is connected to a 
data processing software (Figure 8).  
There various fundamentally different modes of separation which include; 
reverse-phase chromatography (RPC), normal-phase chromatography (NPC), non-
aqueous reverse- phase chromatography (NARP), hydrophilic interaction 
chromatography (HILIC), ion-exchange chromatography (IEC), ion-pair chromatography 
(IPC), size-exclusion chromatography (SEC) (TABLE I) [46]. Each of these techniques 
has its own advantages and disadvantages, which ultimately determine their suitability as 
separation techniques hyphenated to MS. 
Reverse-phase chromatography (RPC) or Reverse phase liquid-chromatography 
(RPLC) is the most commonly used method and is utilized in this work. It’s based on the 
partitioning of the analyte between a polar mobile phase and a hydrophobic stationary 
phase on the column. The mobile phases used includes a mixture of aqueous (e.g. water 
or buffer) and organic solvents (e.g. methanol or acetonitrile). The stationary phase is a 
non-polar alkyl hydrocarbons i.e., C-8 or C-18 chains bonded on silica support (or other 
inert supports) in the analytical column [47]. In RPLC, the non-polar compounds are 
retained longer on the column than polar compounds, but by varying the percent content 
of the organic additive in the mobile phase, analytes can be eluted. Therefore, the choice 
of the solvents used, the modifiers (acids, bases or ion pairing agents) added, and the pH 
selected, greatly influence the selectivity and the retention of the analytes in RPLC. 
 RPLC is the widely used method of separation because if its ability to analyze 
polar, medium and non-polar analytes as well as ionic analytes in some cases. In addition, 
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Figure 8: Liquid chromatography  system
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TABLE I: MODES OF LC SEPARATION
Chromatographic 
Mode Abrv. Column Type Mobile Phase Application
Reverse-phase 
chromatography RPC
Non-polar 
(e.g. C18)
Polar mixture of water 
and organic solvent (e.g. 
acetonitrile)
Water-soluble 
samples
Normal-phase 
chromatography NPC
Polar ( e.g. 
unbonded 
silica)
Less-polar (than 
stationary phase) mixture 
of organic solvents (e.g. 
hexane, ethyl ether, 
chloroform, methylene 
chloride)
Water-insoluble 
samples, isomer 
separation, and 
preparative HPLC
Non-aqueous 
reverse-phase 
chromatography
NARP Non-polar (e.g. C18)
Mixture of organic 
solvents (e.g. ACN + 
methylene chloride)
Very hydrophobic 
samples
Hydrophilic 
interaction 
chromatography
HILIC
Polar (e.g. 
silica or 
amide-
bonded)
Mixture of water organic 
solvents (e.g. ACN + H2O
Highly polar 
samples that are 
poorly retained by 
reverse-phase 
mode
Ion-exchange 
chromatography IEC
Usually an 
organic resin 
that has 
charged 
groups able to 
bind ions of 
opposite 
charge
Aqueous solution of a salt 
with buffer.
Separating 
ionizable samples, 
large biomolecules 
(e.g. proteins, 
carbohydrates)
Ion-pair 
chromatography IPC
Non-polar 
(e.g. C18)
Polar mixture of water 
and organic solvent (e.g. 
ACN) w/ an ion-pairing 
reagent (e.g. 
alkylsulfonates, 
trifluoroacetic acid) that 
interacts w/ sample ions 
of opposite charge
Acids and bases 
that are weekly 
retained by 
reverse-phase
Size-exclusion 
chromatography SEC Inert Aqueous or organic
Large 
biomolecules, 
polymers. 
Separates by 
molecular weight.
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RPLC is more compatible with MS in terms of the solvents used and flow rates at which 
they enter the MS. Unlike the other separation techniques such as, NPC or IEC that  
require the use of nonvolatile salts (i.e. phosphates), additives (i.e. ion pairing agents) and 
organic solvents that tend to significantly reduce the MS detection signal [4]. 
The pharmaceutical industry works towards the reduction in the sample analysis 
time and high sample throughput, without compromising the separation efficiency and 
selectivity of the analytes of interest. To achieve this, various columns have been design 
with a versatile stationary phase and technology is moving towards shorter lengths and 
small particle sizes. Ultra high performance LC (UPLC) has also emerged that use 
columns with sub-2 µm particle size and an LC system that can handle high pressures. 
UPLC has the advantage of decreased run time and increase sensitivity over conventional 
LC method hence; it provides the needed high sample throughput without affecting the 
chromatographic performance. 
Nevertheless, the optimization of the separation process is also influenced by the 
choice of detector. The “start of the art” configuration i.e., hyphenation of LC to mass 
spectrometry (MS), has proved to be more efficient and of high selectivity compared to  
most techniques, therefore, it’s the method of detection used in this work. 
1.2.1.2 Mass spectrometry (MS)  
Mass spectrometry is a powerful tool that is highly selective, and provides a 
wealth of structural information useful for analysis and quantitation of small molecules. 
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The main components of a mass spectrometer are shown in Figure 9 and include; a 
method to introduce the compounds into the MS. Normally, a direct flow injection can be 
done using a syringe pump, which is the fastest approach or a flow injection analysis 
(FIA) by LC can be used [48]. The sample in solution is then evaporated in the ion source 
and gas phase ions are formed. After which, this ions enter the mass analyzer where the 
electromagnetic field separates the ions based on their mass to charge (m/z) ratio and are 
then sent to the detector, that amplifies the signal and generates a mass spectrum which is 
recorded by the computer. 
There various techniques that have been developed to couple the LC to MS and 
serve as an interface i.e., electro spray ionizations (ESI), atmospheric pressure chemical 
(APCI) and atmospheric pressure photo ionization (APPI). ESI and APCI are the 
ionization techniques most commonly used for quantitation. 
In ESI (Figure 10), the sample solution passes through a charged capillary tube 
that has a high electric potential (either positive or negative) applied at the end of it. This 
causes a solvent spray to form, made up of charged droplets. The flow of the nebulizing 
gas in the same directions, helps increase the spray efficiency, whereas, the nitrogen gas 
drying gas assists with the desolvation. As the solvent evaporates and the droplet 
decreases in size, the surface charge density is increased and so is the repulsion force. 
The droplets break up and then charged ions are formed. The formation of these ions is 
also depends on the mobile introduced and could results in formation of other adducts in 
the mobile phase [49]. Therefore the use of volatile buffers (i.e., ammonium formate, 
ammonium acetate etc) containing counters ions could help suppress this phenomenon. 
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Figure 9: The basic components of a mass spectrometer 
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Figure 10: A schematic of an ESI interface 
http://www.particlesciences.com/news/technical-briefs/2009/mass-spectrometry-bioanalysis.htm
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ESI is considered a “soft ionization technique” and it has the ability to analyze 
polar to ionic compounds, as well as, high molecular weight bio-molecules i.e. proteins. 
APCI (Figure 11) on the other hand, differs with ESI in that ionization occurs in 
the gas phase and not in solution. The sample is sprayed through a capillary, then a 
nebulizing gas assists to evaporate the liquid in the source and the sample is vaporized 
with the heater gas. The vapor formed collides with sample solvent molecules ionized by 
the corona discharge, generating ions. APCI can analyze less polar compounds, and it’s
less prone to matrix effects; however, it requires the compounds to be thermally stable.  
The mass analyzer is the heart of the MS. It basically distinguishes and separates 
molecular ions and the ions formed from the dissociated products according to their m/z
ratio, before finally entering the detector: where they are measured and their abundance 
determined. The Mass analyzer is operated under high vacuum, such that the ions that 
exit the detector travel with a sufficient yield. There various types of mass analyzers i.e., 
quadrupole (Q), ion trap (IT), and time of flight (TOF), but not all are applicable for drug 
analysis and quantitation. In this work, the quadrupole (Q) and ion trap (IT) will be 
discussed. 
Quadrupole mass analyzer are the frequently used for small molecules such as 
drugs and metabolites in the mass range of 80 m/z to 700 m/z [48]. The quadrupole 
analyzer is made of four parallel circular/hyperbolic rods connected together as two 
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Figure 11: A schematic of an APCI interface 
http://www.particlesciences.com/news/technical-briefs/2009/mass-spectrometry-bioanalysis.html
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opposite pairs (Figure 12). These rods are under direct current (DC) potential and radio 
frequency (RF) potential is applied to them in an alternating manner. The ions from that 
enter the quadrupole mass filter from the ion source, are focused along the central axis of 
the rods and oscillate in X, Y and Z directions i.e., some have stable trajectories other 
have unstable ones. The ions traveling along the Z axis are the only ones affected by the 
total electric field, resulting in stable trajectories and are able to reach the detector. All 
the other ion are filtered out ; due to the unstable trajectories they hit the rods and are not 
detected [50, 51]. 
The quadrupole can be operated in two modes: the scan mode or single ion
monitoring (SIM) mode. In the scan mode, the amplitude of the DC and RF voltages are
set to monitor a series of masses in a certain mass range. This mode is suitable for 
qualitative work. In the SIM mode, the MS is tuned to a particular m/z window that 
overlaps with the ion of interest hence, more sensitive and suitable for quantitation. The 
SIM mode enables the determination of the structure of the compound based on the 
precursor (parent) / molecular ion; the ion with the highest m/z value which represents the 
molecular weight (MW) of the compound of interest. This mode is not selective when 
components in the sample matrix have the same m/z with the target analyte [51]. 
Ion trap mass analyzer as depicted in the name, traps ion prior to reaching the 
detector. The trap consists of; an entrance end cap electrode, ring electrode on two sides 
and an exit end cap electrode (Figure 13). The voltages applied to the electrodes enable 
ions to enter the trap and based on these voltages, as well as, the m/z of the ions, they 
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Figure 12: Quadrupole mass analyzer [50] 
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Figure 13: Ion trap mass analyzer [50]
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oscillate with stable trajectories. When the voltages are altered, the ions are destabilized 
and exit the trap into the detector. The limitation of the ion trap is that, as ions of the 
same charge accumulate in the trap, they tend to repel one another. To over come this 
problem inert gases i.e., nitrogen and helium have been added into the trap to stabilize the 
ions and minimize collision with the sides of the trap [50]. 
1.2.1.3 Tandem mass spectrometry (MS/MS) 
In addition to single quadrupole or ion trap use, the quadrupole analyzer can be 
operated in the MS/MS mode where by multiple analyzers (of the same or different kind) 
are used in tandem i.e. the triple quadrupole (QqQ) and the quadrupole ion trap (QTrap).  
The QqQ instrument consists of two quadrupoles, separated by collision cell. The 
first quadrupole selects the precursor ion, the second quadrupole is the collision induced 
dissociation (CID) cell where the ions are fragmented (at different degrees) in the 
presence of a collision gas. The resulting fragments are then sent into the third 
quadrupole, where they are analyzed in scan mode or by single ion monitoring (SIM).
The QTrap works slightly different than the QqQ in that, the instrument consists of a 
quadrupole, which selects the precursor ion and an ion trap which as discussed traps ions. 
The ions undergo fragmentation by CID in the same trap and then isolated and detected.
In MS/MS there various modes used (Figure 14), but in this work, we only 
consider the selected-reaction-monitoring (SRM) also known as the multiple-reaction-  
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Figure 14: Tandem MS modes of operation 
http://www.lamondlab.com/MSResource/LCMS/MassSpectrometry/MSMSOverview.php 
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monitoring (MRM). In this mode, fragmentation is carried out in Q2 with a collision gas; 
Q1 and Q3 are used to select specific molecular (precursor) and product ions (m/z) 
respectively, without scanning (Figure 15). MRM is similar to the SIM mode; however, 
the ions selected in Q1 are only detected if they fragment by the selected mass transition 
of precursor/product ion pair. This allows for the structural analysis of the compound of 
interest based upon the fragmentation pattern, thus offers a better sensitivity with an 
added selectivity for quantitative analysis of complex sample matrices [51]. 
1.2.2 Stable isotope dilution (SID)-LC-MS/MS 
Stable isotopes are naturally occurring elements that have the same number of 
protons, but differ from each other in molecular masses due to having different number 
neutrons. They have extremely low abundances in nature (TABLE II) i.e., the abundance 
of 2H relative to 100 parts of 1H is 0.015. Therefore, these stable isotopes are used in 
combination with LC-MS/MS to provide the highest possible analytical specificity for 
quantitative analysis [52].  
Stable isotope analogs are added to complex biological matrices as internal 
standards (IS) prior to sample preparation to correct for matrix effect, loss of analyte and 
variation in sample extraction, hence, improve the method’s precision and accuracy. In 
this case, the response ratio between the analyte and labeled IS, is used to construct a  
33 
Figure 15: Schematic of triple quadrupole(QqQ) 
http://www.mrmatlas.org/mrmassays.php 
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TABLE II:LIST OF COMMON ORGANIC ELEMENTS AND THEIR ISOTOPES[52] 
Element m/z % Natural Abundance
1H 1.008 99.985
2H 2.014 0.015
12C 12.000 98.89
13C 13.003 1.11
14N 14.003 99.63
15N 15.000 0.37
16O 15.995 99.759
17O 16.999 0.037
18O 17.999 0.204
28Si 27.977 92.21
29Si 28.976 4.70
30Si 29.974 3.09
32S 31.972 95.05
33S 32.968 0.76
34S 33.967 4.22
35 
standard calibration curve and determine the amount of the analyte in the unknown 
samples. 
In addition, since stable isotope labeled analogs of a compound share the same 
chemical structure and properties as the unlabeled compound, they behave in a similar or 
identical manner. Therefore, they can be used as surrogates to verify the presence of the 
analyte of interest, as well as, quantify the analyte in complex matrices, due to the lack of 
blank (analyte-free) matrices. In this work, stable isotope dilution (SID)- LC-MS/MS was 
employed in Chapter 4 for specific and accurate measurement of the metabolite of BPA 
in human urine samples. 
1.3 Sample preparation for complex matrices  
Sample preparation is critical prior to LC-MS/MS analysis especially when 
dealing with complex matrices. This helps to remove any impurities and other 
endogenous matrix components that could possibly interfere with the MS detection. The 
techniques commonly used include; “dilute and shoot”, protein precipitation (PPT), 
liquid-liquid extraction (LLE), salting-out assisted liquid-liquid extraction (SALLE) and 
solid phase extraction (SPE) [53]. 
Dilute and shoot as the name implies, the samples are simply diluted and directly 
injected into the LC-MS/MS. This method is applicable in case where the concentration 
of the analyte in the sample matrix is relatively high and the matrix effect is not a 
concern. 
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In protein precipitation (PPT), a precipitation agent/solution i.e., an organic 
solvent is added to a volume of plasma or serum sample, which typically contain 
proteins. This disrupts protein association with each other and the proteins precipitate out 
of solution. The sample is then centrifuged and the supernatant removed and analyzed. 
PPT technique is popular due to its ease of use and simplicity; however, it does not 
sufficiently remove all the interferences and as a result matrix effect is common with this 
technique. 
Salting-out assisted liquid-liquid extraction (SALLE) is similar to PPT but instead 
concentrated inorganic or organic salt is utilized as the salt-out agent to separate the 
aqueous phase from the organic phase after protein precipitation with an organic solvent. 
The commonly used salts include; ammonium sulfate, zinc sulfate, sodium chloride and 
potassium carbonate. However, some of these salts are detrimental to the lifetime of the 
column and MS. Therefore, salts that are more compatible with MS i.e., ammonium 
acetate, ammonium formate, and saturated ammonium bicarbonate can be used. 
In liquid-liquid extraction (LLE) the compounds are extracted based on solubility 
in two different immiscible liquids i.e. water and organic solvent such as those in TABLE 
III. Since most biological matrices are in aqueous solution, the organic solvents with a 
density less than that of water will settle at the top and can be removed easily. Also, 
depending on the polarity of the analyte and that of the solvent, analytes can be 
effectively extracted from one solvent into another by vortex-mixing, then centrifuged 
and the organic layer is removed, evaporated and the residue reconstituted for analysis. 
The recovery and selectivity of LLE for the analyte is not only dependant on the 
solubility of the analyte but also the pKa, the solution pH and ionic strength. 
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TABLE III: COMMON SOLVENTS USED FOR LLE
Solvent Density (g mL-1)
Hexane 0.685
Diethyl ether 0.713
Methyl-tert butyl ether 0.740
Methylethyl Ketone 0.805
N-butanol 0.810
Ethyl Acetate 0.897
Methylene Chloride 1.33
Chloroform 1.48
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By manipulating these factors LLE can provide clean extracts with high recoveries. 
Solid phase extraction (SPE) is based on the affinity of solutes in mobile phase for 
the stationary phase, similar to LC. The analytes are retained on the stationary phase, 
packed in a column/cartridge. There are various forms of stationary phases or sorbents 
used, some include: silica, polymeric based (C8, C18), cation and anion exchange, as 
well as mixed –modes. SPE is performed in various steps shown in Figure 16. First, there 
is a conditioning step to activate (wet) the sorbent, which is normally done using an 
organic solvent. Then, the sorbent is equilibrated with the sample solvent or loading 
buffer prior to the analyte sample being added on to the sorbent. Once the sample is 
loaded, the analyte interacts with the sorbents upon contact and it’s retained; any other 
impurities can be washed off. Finally, the analyte is eluted off the sorbent with a stronger 
elution solvent that can dissociate the analyte-sorbent interactions.   
1.3.1 Matrix effect  
When LC-MS/MS is used for quantitation of drugs in highly complex matrices 
(i.e., biological fluids, or plants samples), the presence of interfering components in these 
matrices co-elute with analyte of interest and hinder ionization [54]. This leads to a less 
volatile solution, which affects the efficiency of droplet formation and the evaporation 
process. Consequently, it alters the amount of charge (ionization) reaching the detector, 
such that the signal is either suppressed or enhanced. Matrix effect has been known as the 
“achilles heel” (a fatal weakness in spite of overall strength results) of MS quantitation. 
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Figure 16: SPE procedure 
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Matrix effect can seriously affect the LC-MS/MS analytical assay: it could result 
in an increased background noise, random variation in the signal and decreased 
sensitivity, limiting the accuracy and precision of the method [55].  Matrix effect can 
occurs as a result of poor sample clean-up, presence of endogenous lipids, use of ion-
pairing additives i.e., triethylamine (TEA) , or presence of salts in the sample etc. 
Therefore, the use of column switching valve could divert the salts into waste and 
decrease the contamination of the MS. However, to minimize matrix effect, an 
appropriate sample preparation method should be developed. For example LLE has been 
found to provide cleaner samples than PPT. Also proper optimization of the separation 
conditions and choice of ionization technique can help minimize or eliminate this 
problem [54].  
Matrix effect is evaluated in two ways (Figure 17). First, by post-column infusion 
whereby, the analyte is infused into the MS with a syringe pump, at the same time, a 
blank matrix is injected on to the column and eluted by the mobile phase. Normally, a 
steady response should be observed on the mass chromatograms; however, in the case of 
ion suppression or enhancement the signal will decrease or increase respectively, at a 
certain point on the chromatograms. This is representative of the time at which the 
inferences elutes off the column. This method is qualitative and would require each 
analyte to be infused individually each time, so it’s not ideal [54].  
The other method used is post-extraction addition where by the analyte is spiked 
at a certain concentration into the extracted blank matrix and the signal response 
compared with the corresponding concentration in a neat solution (equation 1.1). 
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The matrix effect is assessed as matrix factor (MF) where a value of 1 indicates no matrix 
effect is observed whereas <1 indicates ion suppression and >1 is ion enhancement. 
 
 
Peak Area of Analyte in Extracted Matrix
MFanalyte Peak Area of Analyte in S
=
olvent
  (1.1) 
Selection of an appropriate internal standard (IS), is important since it can be used 
to correct not only variability in sample extraction, LC injections but also MS ionization 
and hence matrix effect. Ideally, when analyzing complex biological matrices a stable 
isotope labeled IS would be appropriate because it has similar physicochemical properties 
to the analyte and would behave in a close manner or identical to the analyte in all stages 
of the analytical assay (i.e. extraction, injection, ionization etc). However, heavy isotopes 
are not readily available for some compounds, which would require custom synthesis and 
it’s relatively expensive. As an alternative, a structural analog of the compound (i.e., one 
that differs by one functional group) can be used, despite the fact that they could be less 
representative of the analyte of interest and differ in the retention time and ionization 
properties compared to analyte of interest. 
When the IS is used, matrix effect of the IS is also calculated using equation 1.2 
and the normalize MF reported (equation 1.3). 
 
 
Peak Area of IS in Extracted Matrix
MFIS Peak Area of IS in Sol
=
vent
  (1.2) 
MFanalyteIS Normalized MF or MF = normalized MFIS
    
  (1.3) 
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Figure 17: Method used to assess matrix effect [54] 
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1.4 Method validation 
The U.S Food and Drug administration (FDA) requires bioanalytical methods 
developed for quantitation of small molecules be validated before they are implemented 
into preclinical and clinical trials. The FDA guidances are standard procedures that 
demonstrate that the analytical method developed is reliable and reproducible for analysis 
of small molecules in biological matrices. The parameters required for validation include 
selectivity, sensitivity, linearity of the calibration curve, matrix effect, recovery of the 
assay, accuracy, precision, and stability studies [56-58]. 
Below is summarized protocol of analytical method validation used in our laboratory [59] 
1. Selectivity is the ability to measure and differentiate analytes of interest in presence of 
interfering components. 
a. 6 sources of blank matrix samples are used and the mass chromatograms at m/z of 
analyte and m/z of IS is recorded (5 replicates for each sample).  
b. If interference is present in matrix blank at the same  retention time (tR) and the 
same m/z of analyte and IS, their mean peak area should be ≤ 20% of the mean 
peak area of the analyte at lower limit of quantitation (LLOQ), as well as, that of 
the IS.   
2. Sensitivity (correctly should be LLOQ), which is the lowest amount that can be 
quantified with an acceptable precision and accuracy. 
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c. LLOQ should be determined by analyzing at least 5 replicates of the sample at the 
LLOQ concentration on at least one of the validation days.  Intra-run precision 
(%CV) and accuracy (%RE) should be ≤± 20%. 
d. Also, the analyte with it’s IS are determined at the LLOQ in 6 sources of blank 
matrix and the mass chromatograms at m/z of analyte and m/z of IS (5 replicates 
for each sample) obtained. Using a calibration curve, the accuracy and precision 
can be obtained at the LLOQ. The %CV and %RE should be ≤± 20%. 
2. Calibration standards 
a. Matrix blank: matrix sample without IS 
b. Zero standard: matrix sample with IS 
c. 6 to 8 non-zero standards 
d. The acceptance criteria (at least 75% of standards should meet the criteria):  
LLOQ standard ≤ 20% and all other standards ≤ 15%
3. Upper limit of quantitation (ULOQ):  Although not required, the accuracy and 
precision may be determined in a similar manner as LLOQ but %CV and %RE should 
be ≤ 15%.
4. Validation batches:  Analyzed at least 3 batches (i.e., calibration curves) for accuracy 
(%RE) and precision (%CV).
5. QC samples 
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a. QCs are added in multiples of three concentrations (low, mid, high) with 6 or a 
minimum of 5% of the total number of unknown samples in each analytical batch 
b. At least 67% (4 out of 6) of the QC samples should meet the acceptance criteria 
(LLOQ ≤ 20%, all others ≤ 15%); 33% of the QC samples (not all replicates at 
the same concentration) can be outside the acceptance criteria.   
c. If there are more than 2 QC samples at a concentration, then 50% of QC samples 
at each concentration should meet the acceptance criteria. 
6. Preparation of calibration standards and QC samples:  Calibration standards and 
QC samples can be prepared from the same spiking stock solution if the solution 
stability and accuracy have been verified.  A single source of matrix may also be used 
if selectivity has been verified.
7. Positional differences:  During validation of the method, calibration standards and 
quality control samples are analyzed in a predefined order as follows:
a. One set of calibration standards is place at the beginning of the run (front curve) 
b. Then quality controls are analyzed and any other validation samples in the middle 
of the run, distributed randomly or placed in such a sequence as to help positional 
differences. 
c. One set of calibration standards is analyzed at the end of the run (back curve). 
d. A blank matrix sample or zero standard is placed after the high concentration 
sample (ULOQ) to assess carryover.
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8. Placement of samples:  Calibration curve samples, blanks, QCs, and study samples 
can be arranged as considered appropriate within the run, and support detection of 
assay drift over the run.
9. Recovery 
a. The extent of recovery of analyte and IS should be consistent, precise, and 
reproducible. 
b. Spiking method (can be used only for off-line extraction) 
i. Samples include a) Blank matrix + Analyte and IS 
              b) Extracted blank matrix + Analyte and IS.  
ii. 5 replicates of QC samples at 3 concentration levels (low, mid, high) are 
determined. 
iii. A blank matrix sample or zero standard is placed after the high 
concentration sample (ULOQ) to assess carryover.
iv. Peak areas (PA) of analyte and IS are obtained and recovery calculated 
using equation 1.4 -1.6. 
 PA of  Analyte in MatrixRecovery = x 100%analyte PA of  Analyte in Extracted Matrix
       
  (1.4) 
 
IS
PA of  IS in Matrix
Recovery = x 100%
PA of IS in Extracted Matrix
       
  (1.5) 
47
RecoveryanalyteIS Normalized Recovery or Recovery = normalized RecoveryIS
    
  (1.6) 
10. Matrix effect  
a. An absolute MF or IS-normalized MF of about 1 is not necessary for a reliable 
bioanalytical assay.  However, highly variable MF in individual subjects would be 
a cause for the lack of reproducibility of analysis.  If IS is a heavy isotope, IS-
normalized MF should be closed to 1. 
b. The absolute MF (or IS-normalized MF) for 6 individual lots of matrix is 
determine and %CV should be less than 15%.  If stable isotope IS is used, it is not 
necessary to determine the IS-normalized MF in 6 different lots. 
c. Spiking method (can be used only for off-line extraction) 
i. Samples:  a) Extracted blank matrix + Analyte and IS 
       b) Solvent + Analyte and IS. 
ii. 5 replicates of QC samples at 3 concentration levels (low, mid, high) 
are determined. 
iii. Peak area (PA) of analyte and IS are obtained   
iv. The MF is calculated using equation 1.1 - 1.3 
11. Accuracy and precision 
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a. QC samples at a minimum of 3 concentrations (low, mid, and high) plus dilution 
QC. 
b. Low QC:  near the LLOQ (up to 3 x LLOQ). 
c. Mid QC:  middle of the range (at about the geometric mean of low and high QC. 
concentration) 
d. High QC: near the high end of the range, about 70% to 85% of ULOQ. 
e. Dilution QC:  sufficient to cover highest anticipated dilution. 
f. Intra-run accuracy and precision at least 5 replicates at each concentration, the 
mean, SD, %CV, and %RE are determined (%CV and %RE ≤ 15%). 
g. Inter-run accuracy and precision at least 5 parallels at each concentration, the 
mean, SD, %CV, and %RE are determined (%CV and %RE ≤ 15%).
12. Stability 
a. Stock solution: minimum of 6 h at room temperature. 
b. Post-preparative (extracted samples/autosampler tray):  Longest time from 
preparation through sample analysis.  Assessed against fresh standards, except for 
autosampler re-injection reproducibility. 
c. Benchtop:  at ambient temperature (or temperature used for processing of 
samples) to cover the duration of time taken to extract the samples (typically ca. 
4-24 h). 
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d. Freeze-thaw: QC samples at minimum of 2 concentrations (low, high), 3 cycles, 
completely thawed, refrozen at least 12 h between cycles, at anticipated 
temperature of sample storage. 
e. Long-term:  Covers longest time from collection to final analysis for any sample 
in study.  3 aliquots at low and high concentrations are analyzed with fresh 
standard curves and compare against intended (nominal) concentrations.  Long-
term stability can be completed post validation.  
13. Replicate analysis 
a. In general, samples can be analyzed with a single determination without 
replicate analysis if the chromatographic assay method has acceptable 
variability as defined by the validation data.   
b. Duplicate or replicate analysis can be performed for a difficult procedure 
where high precision and accuracy may be difficult to obtain. 
14. Multiple analytes in a run:  Samples involving multiple analytes in a run should 
not be rejected based on the data from one analyte failing the acceptance criteria.
15. Rejected run:  The data from rejected runs need not be documented, but the fact 
that a run was rejected and the reason for failure should be reported. 
1.5 LC-MS/MS method development workflow  
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To develop a quantitative LC-MS/MS method, the following work flow could be 
utilized (Figure 18). First, the mass spectrometer (MS) is tuned by infusion or LC flow 
injection of the analytes of interest (i.e. drug compound or metabolite) and internal 
standard (IS) in the appropriate mobile phase to establish the detection parameters. The 
molecular ion spectrum is obtained to identify the compounds and then to enhance the 
specificity of the MS, multiple-reaction-monitoring (MRM) is used where by, the 
compounds undergo fragmentation to obtain the product ion spectra. Then, specific mass 
transitions i.e., parent/ product ion pairs are selected for quantitation of the analyte and 
IS.  
There after, the LC method is developed by selecting the best conditions i.e., the 
mobile phase, column, flow rate, pH, etc, that provide sufficient separation and baseline 
resolution of the analyte from interfering components in the sample matrix.  It’s
important that the peak shapes are symmetrical and the retention times reproducible for 
accurate peak integration. 
After the LC-MS/MS method has been established, a sample preparation method 
is developed to extract the analyte and IS from complex matrices (i.e., plant, plasma, 
urine etc.). The effectiveness of the sample preparation method to extract the analytes and 
minimize or eliminate the interferences in the sample matrices is evaluated by 
preliminary recovery and matrix effect studies. If the sample extraction method is not 
satisfactory other sample preparation techniques are tested as well as, the LC-MS/MS 
method is redeveloped or fine-tuned to provide maximum sensitivity and selectivity.  
Last but not least the optimized method is validated according to the FDA 
guidance and once all the criteria’s are met the method is applied to real samples.
51 
Figure 18: LC-MS/MS method work flow
52 
1.6 Conclusion 
This chapter introduces the importance of quantitative methods of analysis in the 
early stages of drug discovery and development, as well as, biomonitoring studies. Its 
focus is on development of LC-MS/MS methods for plant derived anticancer agents and 
synthetic estrogen. The capabilities of LC-MS/MS as the superior method of choice have 
been discussed as well as, sample preparation techniques that would be appropriate when 
analyzing complex matrices. An overview of stable isotope dilution (SID)- LC-MS/MS 
has been presented and the FDA requirements of newly developed LC-MS/MS method 
have been discussed in detail. Finally, a general work flow of LC-MS/MS method 
development has been summarized at end of the chapter. 
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CHAPTER II 
QUANTITATIVE DETERMINATION OF (-)-SECURININE, A POTENTIAL 
ANTICANCER AGENT IN SECURINEGA SUFFRITICOSA PLANT BY LC-
MS/MS 
2.1 Introduction 
Securinega suffruticosa (Figure 1) is a sub-tropical semi-shrub of the 
Euphorbiaceae subfamily that is widely distributed in north eastern parts of Asia [1].  It 
has mostly been used in traditional Chinese folk medicine as diuretics, antipyretics and 
for the treatment of hepatic disorders, the after-effects of infantile paralysis and against 
skin eruptions [2].  The main active constituent of this plant is securinine, which is the 
major alkaloid in the plant’s leaves and the minor alkaloid in the plant’s roots [3].  
Securinine was first isolated from its natural source in 1956 and its structure (Figure 2) 
and absolute configuration were established by spectroscopic methods in 1962 then later 
confirmed 1965 by X-ray crystallography [4-6]. Securinine’s stereoisomers i.e., its 
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Figure 1: Securinega suffruticosa plant. (A) Mature leaves (B) Young leaves (C) 
Roots, (D) Stems (E) Bark and  (F) Branches
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Figure 2: Chemical structure of (-)securinine 
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epimer at C-2; allosecurinine [7] and its enatiomers; virosecurinine [8] and 
viroallosecurinine [9] have also been isolated from natural plant sources and 
characterized [4-9]. 
(-)-Securinine (SE) has been reported to have a wide range of pharmacological 
activities. It has been mainly used for the treatment of non-cancer related diseases such as 
poliomyelitis, aplastic anemia, multiple sclerosis [10, 11] and diseases related to the 
central nervous system (CNS) acting as a GABA receptor antagonist [12, 13]. Recently 
SE has been found to be a  macrophage activator [14], and an inhibitor of parasitic 
(Toxoplasma gondii) proliferation [15], which means it could potentially be used in the 
treatment of infectious diseases. SE has also been found to have anticancer properties i.e., 
induce apoptosis in human leukemia cells (HL-60) [16]; SW480 [17]  and in  p53-
deficient colon cancer cells [18]; and  acts as a myeloid differentiation inducing agent in 
acute myeloid leukemia with increased efficacy and low toxicity [19]. 
A rapid and reliable analytical method is required to ensure quality, efficacy and 
safety of SE herbal products. To support the pharmaceutical development and 
toxicological studies of SE, a sensitive and reliable analytical method is needed for 
quantitative analysis of the drug in Securinega suffruticosa plant. Based on a recent 
literature search, several analytical methods for SE determination in raw plant material 
have been described [20]. A majority of this methods are based on old and antiquated 
conventional methods i.e., colorimetric [21], polarimetric [22] , hydroxylamine-sulfanilic 
acid [23] and titrimetry [20]. The current analytical methods i.e., HPLC-UV [24, 25], CE-
UV [26] and GC-MS [27] are mainly used for analysis of biological samples and are 
limited in terms of selectivity for the determination of SE in raw plant material.
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In this work, an LC-MS/MS method for quantitative determination of SE in 
Securinega suffruticosa has been developed. A liquid-liquid extraction (LLE) procedure 
using ethyl acetate was developed for sample preparation. Isocratic separation of SE was 
achieved on a Gemini®-Nx C18 column using a 38% acetonitrile and 62% 20.0 mM 
ammonium acetate as the mobile phase. Quantification was carried out by positive 
electrospray tandem mass spectrometry (ESI+–MS/MS) in multiple-reaction monitoring 
mode (MRM). The LC-MS/MS method developed has been validated and was applied to 
the quantitative analysis of the distribution and levels of SE in different parts of 
S.suffruticosa plant (i.e., leaves, roots, stems, bark and branches). 
2.2 Experimental 
2.2.1 Chemicals and solutions 
(-)-Securinine or SE (C13H15NO2, CAS Registry Number: 5610-40-2) was 
obtained from LKT Laboratories (St.  Paul, MN, USA).  Ammonium acetate (NH4Ac), 
dimethyl sulfoxide (DMSO), ethyl acetate and ammonium hydroxide (NH4OH, 28-30 % 
wt NH3), were purchased from Fisher Scientific (Pittsburgh, PA, USA).  HPLC-grade 
acetonitrile was from Pharmco-AAPER (Shelbyville, KY, USA).  Deionized water was 
obtained from a Barnstead NANOpure™ water purification system (Thermo Scientific, 
Waltham, MA, USA) with the resistance reading of 18.2 MΩ.
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The stock standard solution of SE (18.0 mg mL-1) was prepared by dissolving 
proper amounts of accurately weighed compound in a known volume of DMSO. The 
aliquots (20.0 µL) of the stock solutions were stored at - 80°C prior to their use.  SE 
working standard solutions (0.00, 10.0, 20.0, 30.0, 100, 200, 300, 1.00×103, 2.00×103, 
3.00×103, 1.00×104 and 6.00×104 ng mL-1) were freshly prepared daily by serial dilution 
of the stock standard solution of SE with DMSO. 
An ammonium acetate solution (0.100 M) was prepared by dissolving appropriate 
amounts of the buffer salt in a known volume of water.  20.0 mM ammonium acetate (pH 
6.8) was prepared by a 1/10 dilution of the 0.100 M solution with water.  The mobile 
phase for chromatographic separation was prepared by mixing 38% acetonitrile and 62% 
20.0 mM ammonium acetate, pH 6.8.
2.2.2 Preparation of standard calibrators and quality controls (QCs)  
SE standard calibrators (0.00, 0.500, 1.00, 5.00, 10.0, 50.0,100 and 500 ng mL-1), 
QCs (1.50, 15.0, 150 ng mL-1 ) and dilution QCs (3.00 x 103 ng mL-1)  were prepared by 
diluting every 50.00 µL of the aforementioned SE working standard solutions with 950.0 
µL of the mobile phase in 1.50 mL microcentrifuge tubes (VWR, Radnor, PA, USA). The 
SE dilution QC samples (3.00 x 103 ng mL-1, 10 µL) were diluted by a factor of 100 with 
990 µL of mobile phase prior to sample analysis. The samples were vortex mixed using a 
VWR® Analog Multi-Tube Vortexer (VWR, Radnor, PA, USA) and transferred into 
auto-sampler vials for analysis by LC-MS/MS. 
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2.2.3 Plant material and the preparation of extracts 
Securinega suffruticosa plant (Figure 1) was purchased from Glass Works 
(Stewart, OH) and grown in our laboratory at Cleveland State University. The leaves of 
S. suffruticosa were harvested, dried in a desiccator at room temperature in the dark and 
then finely powdered. Plant leaves were prepared by liquid-liquid extraction (LLE) as 
follows; approximately 20.0 mg powdered plant samples were placed into borosilicate 
glass tubes (16 mm x 125 mm, Fisher Scientific), and then basified with 1.00 mL of 25% 
NH4OH and vortex-mixed for 1 min. The mixture was extracted three times with 5.00 mL 
of ethyl acetate each time. Following each extraction, the sample mixture was vortexed 
for 3 min and subsequently centrifuged for 5 min at 3800 × g (4 °C). The supernatant 
from each mixture was transferred into a clean borosilicate glass tube and then all the 
organic extracts were combined. 10 µL aliquots of the organic extract were diluted 100 
fold with the mobile and vortex-mixed prior to LC–MS/MS.
2.2.4 Instrumentation 
The liquid chromatography tandem mass  spectrometry  system consisted of a 
Shimadzu Prominence UFLC system (Shimadzu, Columbia, MD, USA) with a system 
controller (CBM-20A), two binary pumps (LC-20AD), an online degasser (DGU20A3), 
and an AB Sciex API QTrap 3200 mass spectrometer (AB Sciex, Foster City, CA, USA) 
with a Turbo IonSpray ESI source. The mass spectrometer was connected to the LC-
system outlet via high-pressure polyether ether ketone (PEEK) tubing (0.0625 in. o.d, x 
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0.0100 in. i.d). The system was controlled by AB Sciex Analyst® software (version 
1.5.1) software. 
2.2.5 LC-MS/MS    
The API QTrap 3200 mass spectrometer was operated in positive electrospray 
ionization (ESI+) mode.  It was tuned by flow injection analysis of 1.00 x 103 ng mL-1 SE 
in the mobile phase for both the compound-dependent and the source-dependent 
parameters.  The optimized detection parameters were as follows: curtain (CUR), 20 psi; 
collision-activated dissociation (CAD) gas, 5; nebulizer gas (GS1), 30 psi; turbo heater 
gas (GS2), 45 psi; Turbo IonSpray voltage (IS), 5500V; source temperature (TEM), 
650°C.  High purity nitrogen (99.99%) was used as the nebulizer, auxilliary, collision and 
curtain gases.  The declustering potential (DP), entrance potential (EP), collision energy 
(CE) and collision cell exit potential (CXP), were set at 55, 5.0, 42 and 2.0 V respectively 
for SE .The multiple-reaction-monitoring (MRM) method was used for quantification of 
SE using mass transitions m/z 218.2 → 84.1.   The dwell time for each transition was 805 
ms and the mass resolutions (Q1 and Q3) were set to unit.
Analytical separation of SE was performed isocratically under ambient 
temperature on a reverse-phase Gemini Nx C18 (2.1 mm i.d x 150 mm, 5 μm, 110 Å) 
column (Phenomenex, Torrance, CA, USA) with an inert stainless steel in-line filter (0.5
µm pore, 0.23-µL dead volume) from Upchurch Scientific (Oak Harbor, WA, USA) 
using the mobile phase at a flow rate of 0.200 mL min-1. The injection volume of each 
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sample was 10.0 µL.  Prior to sample analysis, the column was first equilibrated with the 
mobile phase using 20 times of the column volume.  
2.2.6 Data acquisition and analysis 
Data acquisition and peak integration were done using the AB Sciex Analyst® 
software (version 1.5.1) with IntelliQuan-MQII algorigthm.  The averaged peak area 
ratios of SE were plotted against the SE concentrations in standard calibrators for a linear 
regression equation using a weighting factor of 1/x (where x is the nominal concentration 
of the standard calibrator).  The SE alkaloid in S. suffruticosa plant was identified by 
comparison of the retention time (tR) and the MRM spectra, with those of the SE 
standard calibrators. The SE concentrations in the plant samples were back calculated 
with the peak area of SE, using the calibration equation and with dilution factor.
2.2.7 Recovery  
The recovery studies were performed as follows; three different portions of 
S.suffruticosa plant leaves were first extracted using the LLE protocol described in 
section 2.2.3 to generate blank plant matrices. The basic aqueous layer (i.e., blank plant 
matrix ) was obtained from the LLE extract and an aliquot (25.0 µL) of each SE standard 
solutions at low-, mid- and high concentrations (9.00 x 104 ng mL-1, 9.00 x 105 ng mL-1, 
69
9.00 x 106 ng mL-1 mg mL-1) were spiked into the three blank plant matrices. Samples 
were vortex-mixed for 1 min and then extracted three times with 5.00 mL of ethyl acetate 
each time, then centrifuged for 5 min at 3800 × g (4 °C) as described in section 2.2.3. 
Aliquots (10 µL) of the organic extract (supernatant) were diluted 100 fold with the 
mobile, vortexed and analyzed by LC–MS/MS. The recoveries were determined by 
comparing the peak areas of SE in the standard calibrators with those of the 
corresponding samples prepared by spiking SE to the blank plant matrix before LLE. 
2.2.8 Application of the method   
The feasibility of the LC-MS/MS method developed was evaluated by the 
analysis of the distribution and content of SE in different parts of S.suffruticosa plant. 
The plant leaves (young and mature leaves), stems, roots, bark and branches were 
harvested and dried in a desiccator at room temperature in the dark. Prior to analysis, the 
plant samples were finely powdered and prepared by the LLE procedure described, then 
analyzed (n=5) by the LC-MS/MS method.  
2.3 Results and discussion   
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2.3.1 Mass spectrometric detection 
Based on the chemical structure (Figure 2), SE readily acquires a proton than lose 
one in electrospray ionization. Hence the positive electrospray ionization mode was used 
in this work. As shown in Figure 3A (full scan spectrum), SE produced a protonated 
molecular ion [M+H] + at m/z 218.2.Upon fragmentation by collision with ultra-high 
purity helium gas in the mass spectrometer, this molecular ion produced a major fragment 
at m/z 84.1 (Figure 3B). Therefore, the mass transitions m/z 218.2 → 84.1 was chosen for 
quantification of SE in multiple-reaction-monitoring (MRM) mode.
2.3.2 Chromatographic separation  
In this work, the Waters Xterra® RP-18 (2.1mm x 50mm, 3.5μm) and the 
Phenomnex Gemini Nx C18 (2.1 mm i.d x 150mm, 5μm,) were tested for optimal 
separation of SE in S.suffruticosa plant. Both columns were suitable for the separation of 
SE; however, Gemini Nx C18 was chosen for subsequent study because it gave higher 
signal response for SE.
The composition of the mobile phase used for separation was also optimized to 
improve LC separation and enhance MS sensitivity. Acetonitrile was selected as the 
organic modifier due to the greater solvent strength, and higher signal response in mass 
spectrometry than methanol; and ammonium acetate was used as the buffer salt because it 
found to suppress the formation of sodium ion adducts and resulted in greater
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Figure 3: The full scan mass spectra of SE and its major product ions.  
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 detection signal than ammonium formate. Working at this pH, SE (pka = 8.29 ±0.20) 
was protonated and could be retained on the column; however, some peak tailing was 
observed. Therefore, to obtain symmetrical peak shapes, the ionic strength of the buffer 
was optimized. 5mM, 10mM and 20mM ammonium acetate were evaluated and 20mM 
was selected because it resulted in a greater improvement in the peak shape, reduced peak 
tailing and did not compromise the mass spectrometry detection. 
For this work, the optimized mobile phase composition consisted of 38 % ACN 
and 62% 20 mM ammonium acetate, pH 6.8.  Using this mobile phase, separation of SE 
was achieved on the Gemini Nx C18 with retention time of 5.1 min (Figure 4). 
2.3.3 Extraction of SE from S.suffruticosa leaves  
A liquid-liquid extraction (LLE) method was developed for sample clean up prior 
to analysis with LC-MS/MS. SE being a weak acid in solution it was necessary to make it 
neutral for easy extraction into the organic phase.  In this method the plant samples were 
rendered alkaline by adding a base. The alkalinization buffer and pH was found to affect 
the extraction of SE from the S.suffruticosa plant and therefore was optimized. Saturated 
ammonium bicarbonate (NH4HCO3) pH 10.2, 0.05% and 25% NH4OH were evaluated 
and the latter base was used in this work, because it enabled efficient extraction of SE 
from S.suffruticosa plant samples. 
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Figure 4: The mass chromatograms of SE standards (A) double blank (no SE 
detected) (B) lowest standard calibrator (LLOQ, 0.500 ng mL-1) (C) highest 
standard calibrator (ULOQ, 500 ng mL-1). 
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Various organic solvents such as dichloromethane (DCM), chloroform, methyl 
tert-butyl ether (MTBE) and ethyl acetate (EAC) were tested for use in the LLE method. 
DCM and chloroform were prone to form emulsions during the extraction process and 
resulted in poor or incomplete analyte extraction. The extraction recovery of MTBE was 
found to be lower than all the other solvents. LLE performed using EAC with 25 % 
NH4OH resulted in high extraction efficiencies and therefore was chosen for this work. 
Finally, the effect of extraction times was investigated by running four 
consecutive extractions on the same sample. To evaluate the repeatability of the 
extraction procedure, two replicates were performed. As shown in TABLE I, three 
extraction cycles were sufficient to completely extract SE from S.suffruticosa plant, 
therefore, in this work, plant samples were extracted three times with ethyl acetate in the 
LLE method developed. 
2.3.4 Method validation 
The method developed was validated in terms of linear response, lower limit of 
quantitation (LLOQ), recovery, accuracy and precision. 
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TABLE I: THE EFFECT OF EXTRACTION TIMES (N=3) 
Sample 1 Sample 2 Average
Extraction 
time
Measured [SE] 
± SD 
(ng mL-1) 
Measured 
[SE] ± SD 
(ng mL-1) 
[SE] ± SD 
(ng mL-1) 
%Recovery
1 237 ± 1 240 ± 2 239 ± 2 90.2
2 22.8 ± 0.1 24.3 ± 0.2 23.6 ± 1.1 8.92
3 2.20 ± 0.10 2.24 ± 0.15 2.22 ± 0.03 0.840
4 0.242 ± 0.035 0.222 ± 0.026 0.232 ± 0.014 0.051
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2.3.4.1 Linearity and lower limit of quantitation (LLOQ) 
The calibration curves for SE were constructed using seven non-zero standard 
calibrators (i.e., 0.500, 1.00, 5.00, 10.0, 50.0,100 and 500 ng mL-1), and a double-blank 
(without SE). The linear calibration range of 0.500-500 ng mL-1 was established by 
plotting the mean peak areas of SE against the nominal concentration of SE in the mobile
phase.  The calibration equation derived from five validation batches of calibrators using 
a 1/x weighted least-square linear regression was Y=1946(±32) + 225(±64), r2= 0.9997 
(±0.0002). The accuracy and precision of the standard calibrators were ≤ ±16 and ≤ 7 
respectively (TABLE II). 
 In this work, the LLOQ of the method was defined by the lowest concentration on 
the calibration curve (0.500 ng mL-1) with a limit of accuracy and precision within ± 20% 
and 20% respectively.  It was confirmed by analyzing six replicate measurement of SE at 
LLOQ, independent of the calibration standards.  The mean accuracy and mean precision 
of the method at LLOQ were acceptable with ≤ ± 2% of the relative error (RE) and ≤ 8% 
of the coefficient of variation (CV) (data not shown). 
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TABLE II:ACCURACY AND PRECISION OF SE CALIBRATORS (FIVE VALIDATION BATCHES). 
Nominal [SE]
(ng mL -1)
Measured [SE] 
(ng mL-1) SD (ng mL
-1) %RE %CV
0.500 0.422 0.036 -16 7
1.00 1.0 0.1 0 6
5.00 5.0 0.2 0.3 4
10.0 10.9 0.4 9 4
50.0 50.2 2 0.3 3
100 105 3 5 3
500 494 6 -1 1
%RE =[(measured  − nominal )/(nominal )]×100% ; %CV = (SD/mean) x 100%.
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2.3.4.2 Recovery  
  The absolute recovery of the method was determined in low-, mid- and high- QC 
controls (1.50, 15.0, 150 ng mL-1) by comparing the mean peak areas of SE in the 
corresponding QC standard samples (n=5) with those of SE in the spiked in blank plant 
matrix before LLE. TABLE III shows the mean absolute recoveries for SE were 
consistent and ranged from 100-106%.
2.3.4.3 Accuracy and precision 
 The intra-run accuracy and precision were determined by five replicate 
measurements of each QCs (1.50, 15.0, 150 ng mL-1) and dilution QCs (3.00 x 103 ng 
mL-1) in the same validation batch. The inter-run accuracy and precision was determined 
by five parallel measurements of five identical sets of each QC samples in five different 
validation batches.  The accuracy was expressed as percent relative error (%RE) and the 
precision expressed as coefficient variation (% CV).  As shown in TABLE IV the intra-
run accuracy and precisions of all the QCs samples were ≤ ± 3% and ≤ 3% and the inter-
run accuracy and precisions were ≤ ± 7% and ≤ 10% respectively.  These results indicate 
that this method has adequate reproducibility and accuracy. 
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TABLE III: RECOVERY OF SE FROM S.SUFFRUTICOSA PLANT MATRIX  (N = 5) 
Nominal [SE ] 
(ng mL-1)
PASE in extracted 
matrix ± SD (x104)
PASE in mobile phase 
± SD (x104)
RecoverySE ± SD 
(%)
a
1.50 0.317± 0.01 0.316± 0.006 100 ± 3
15.0 3.06 ± 0.06 2.94 ± 0.02 104 ± 2
150 31.8 ± 0.3 29.9 ± 0.2 106 ± 1
PA = Mean peak area.  
aRecovery of SE = (PA of SE in extracted plant matrix / PA of SE in mobile phase) x 100%
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TABLE IV: INTRA- AND INTER-RUN ACCURACY AND PRECISION  
Intra-Runa
Nominal [SE] 
(ng mL-1)
Measured [SE] 
(ng mL-1) SD (ng mL
-1) %RE %CV
1.50 1.5 0.1 0 3
15.0 15.1 0.1 1 1
150 146 1 -3 1
3.00 x10
3c
3.03 x10
3 7 1 2
Intra-Runb
Nominal [SE] 
(ng mL-1)
Measured [SE] 
(ng mL-1) SD (ng mL
-1) %RE %CV
1.50 1.6 0.1 7 8
15.0 15.7 1.6 5 10
150 161 14 7 9
3.00 x10
3c
3.16 x10
3
2.3x10
2 5 7
a Determined by five replicate measurements of each QC sample within a validation batch. 
bDetermined by nine parallel measurements of three identical QC samples at each concentration 
over three validation batches.  
cThe dilution QC was measured by a 100 times dilution.
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2.3.5 Method application  
The developed LC-MS/MS method was applied to the quantitative analysis of the 
distribution and levels of SE in different parts of S.suffruticosa plant (i.e., leaves, roots, 
stems, bark and branches) (Figure 1).The five plant samples were collected and extracted 
by the LLE procedure described. The diluted plant samples, along with standard 
calibrators, QCs and dilution QCs were analyzed (n=5) by the LC-MS/MS method. The 
resultant mass chromatograms are shown in Figure 5. SE was separated from the complex 
plant matrix and detected in Securinega suffruticosa plant extracts with a retention time 
(tR) of 5.1 min.  
As shown in the chromatogram of the plant extract (Figure 5), an additional peak 
was observed at a tR of 2.9 min. The same product ions from MS/MS as SE and closely 
eluted retention times, suggest that it could be an epimeric isomer of SE. Several 
stereoisomeric alkaloids of SE have been isolated in the plants of Securinega species, and 
according Saito et.al [3], the leaves of S. suffruticosa contain SE as the major alkaloid 
and its epimer at C-2; allosecurinine (alloSE) as the minor alkaloid. Whereas, the roots of 
the plant contain alloSE as the major alkaloid and SE as the minor alkaloid [3]. We thus 
hypothesize that the peak observed at tR of 2.9 min with the mass transition m/z 218.2 → 
84.1 is possibly alloSE.
Since the chemical and physiological properties of the epimeric pairs are similar, 
the SE standard calibration curve was used to quantify both SE and alloSE in 
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Figure 5: The mass chromatograms (A) Mature leaves (B) Young leaves 
(C) Roots, (D) Stems (E) Bark and  (F) Branches 
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S.suffruticosa plant. The concentrations of these analytes in the plant samples were back 
calculated with the peak areas of SE, using the calibration equation and with dilution 
factors. The results were reported as milligram (mg)/gram (g) dry plant material (TABLE 
V).  
A great variation in the distribution of SE and alloSE in the different parts of 
S.suffruticosa was observed. The SE content in the plant decreases in the order of; mature 
leaves > young leaves > roots > stems > bark > branches and that of alloSE in the order; 
roots > stems > mature leaves > branches and not detected (ND) in the young leaves and 
bark. It was noted that the older the leaves were, the more they contained SE. The highest 
content of SE was found in plant leaves with a concentration of 7.44 ± 0.05 mg/g of dry 
plant material which corresponds to 0.744% (wt/wt) ± 0.005 whereas, the highest content 
of alloSE was found in the roots with a concentration of 8.43 ± 0.06 mg/g plant which 
corresponds to 0.843% (wt/wt) ± 0.006. These results are in good agreement with levels 
of SE in the S.suffruticosa plant reported in the literature of 0.3 - 0.90% [1].  
2.4 Conclusions 
An LC-MS/MS method for the quantitative determination of SE in Securinega 
suffruticosa plant has been developed and validated. In this work, SE alkaloid was isolate 
from its natural plant material by a liquid-liquid extraction protocol and then separated by 
a Gemini®-Nx C18 prior to detection by tandem MS/MS. This method is fast, highly 
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TABLE V:AMOUNT OF SE IN DIFFERENT PARTS OF SECURINEGA SUFFRUTICOSA PLANT
Securinega suffruticosa [SE] (mg g-1 plant) [AlloSE] (mg g-1 plant)a
Mature leaves 7.44 ± 0.05 0.139 ± 0.004
Young leaves 5.06 ± 0.04 ND
Roots 2.23 ± 0.01 8.43 ± 0.06
Stems 1.21 ± 0.01 1.67 ± 0.04
Bark 0.335 ± 0.005 ND
Branches 0.238 ± 0.004 0.115± 0.003
a ND = not detected 
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 selective, and offers good analyte recoveries, precision and accuracy. The method 
developed was applied to the quantitative analysis of the distribution and levels of SE in 
different parts of S.suffruticosa plant (i.e., leaves, stems, roots, bark and branches) and 
can be useful as a routine quality control assay for the determination of SE and its 
stereoisomers in raw plant material and herbal products. 
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CHAPTER III 
DEVELOPMENT AND VALIDATION OF LC-MS/MS METHOD FOR 
QUANTITATIVE DETERMINATION OF (-)-SECURININE IN MOUSE 
PLASMA 
3.1 Introduction 
Securinine is the major alkaloid found in the plant leaves of Securinega 
suffruticosa, a sub-tropical semi-shrub that has been used in traditional Chinese folk 
medicine [1, 2].  (-)-Securinine (SE) has been reported to have a wide range of 
pharmacological activities such as antagonist of γ -GABAA receptor [3, 4], therapeutic 
agent for the treatment of sequela of poliomyelitis, amyotrophic lateral sclerosis (ALS) 
and aplastic anemia [5, 6], and macrophage activator against Coxiella burnetii [7], or an 
inhibitor of parasitic (Toxoplasma gondii) proliferation [8].  Furthermore, SE has shown 
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anticancer activity such as inducing apoptosis in various human cell lines including HL-
60 [9]; SW480 [10]; p53-deficient colon cancer cells [11] and promote differentiation in 
several acute myeloid leukemia (AML) cells lines ((i.e., HL-60, THP-1 and OCI-
AMLT3) and cells from primary leukemic patients [12].  Moreover, SE was found to 
synergize with other differentiation agents (i.e., all-trans retinoic acid, decitabine and 1, 
25-dihydroxyvitamin D3) which are currently used for treatment of AML; hence it could 
be used to enhance the clinical activity and reduce the toxicity of these agents [12].
To support the preclinical and clinical studies of SE, a quantitative analytical 
method is needed for the measurement of the drug in biological sample.  Based on a 
recent Sci-finder® scholar database search, the current analytical methods for SE analysis 
are mainly qualitative which include HPLC-UV [13, 14], and CE-UV [15].   The only 
quantitative assay reported is a GC-MS [16] method which lacks adequate sensitivity for 
biological samples and has not been validated.
In this work, an LC-MS/MS method for quantitative determination of SE in 
mouse plasma has been developed.   (+)-Norsecurinine (norSE) was used as the internal 
standard (IS).   A salting-out assisted liquid-liquid extraction (SALLE) procedure using 
2.00 M ammonium acetate (volatile salt) was developed for sample preparation.  Isocratic 
separation of SE and the IS was achieved on a reverse-phase C18 column using a 40% 
acetonitrile and 60% 10.0 mM ammonium acetate as the mobile phase.  Quantification 
was carried out by positive electrospray tandem mass spectrometry (ESI+–MS/MS) in 
multiple reaction monitoring mode (MRM). The LC-MS/MS method developed for SE 
analysis has been validated in mouse plasma according to the guidance for industry on 
bioanalytical method validation by the US Food and Drug Administration (US-FDA) [17]
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and the subsequent 2006 white paper of bioanalytical method validation workshop 
[18,19], and applied to the measurement of SE in mouse plasma samples from an animal 
study.   
3.2 Experimental 
3.2.1 Chemicals and solutions 
(-)-Securinine or SE (C13H15NO2, CAS No. 5610-40-2) was obtained from LKT 
Laboratories (St.  Paul, MN, USA). (+)-Norsecurinine or Norse (C12H13NO2, CAS No. 
25472-13-3) was from Ryan Scientific (Mount Pleasant, SC, USA).  Ammonium acetate 
and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St.  Louis, MO, 
USA).  HPLC-grade acetonitrile was from Pharmco-AAPER (Shelbyville, KY, USA).  
Six pooled blank mouse plasma (Na citrated) with specified lot numbers (1H1453-02, 
1R11-0823a, 1R11-0823b, 1H1453-01, 1R11-MS-Nac-0811 and 1R10-NSA-02) were 
purchased from Innovative Research (Novi, MI, USA).  Deionized water was obtained 
from a Barnstead NANOpure™ water purification system (Thermo Scientific, Waltham, 
MA, USA) with the resistance reading of 18.2 MΩ.
Stock standard solutions of SE (2.00 mg mL-1) and norSE (1.20 mg mL-1) were 
prepared individually by dissolving proper amount of each accurately weighed compound 
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in a known volume of DMSO.  Aliquots (20.0 µL) of the each stock solution were stored 
at - 80°C prior to use.  SE working standard solutions (12.0, 24.0, 36.0, 120, 240, 360, 
1.20 x 103, 2.40 x 103, 1.08 x 104, 1.20 x 104 and 3.60 x 104 ng mL-1) were prepared daily 
by serial dilution of the stock standard solution of SE with DMSO.  Working IS solution 
(1.20 x 103 ng mL-1) was prepared by three sequential dilutions (1/10) of the stock IS 
solution in DMSO.   
  Ammonium acetate solutions (0.100 M and 2.00 M) were prepared by dissolving 
appropriate amounts of the buffer salt in known volumes of water.  10.0 mM ammonium 
acetate (pH 6.8) was prepared by a 1/10 dilution of the 0.100 M solution with water.  
The chromatographic mobile phase consisting of 40% acetonitrile and 60% 10.0 mM 
ammonium acetate was prepared by mixing 200 mL of acetonitrile with 300 mL of 10.0 
mM ammonium acetate.
3.2.2 Preparation of plasma calibrators and quality controls (QCs)  
SE plasma calibrators (0.600, 1.20, 6.00, 12.0, 60.0, 120 and 600 ng mL-1), QCs 
(1.80, 18.0, 540 ng mL-1) and dilution QC (1.80 x 103 ng mL-1) were prepared by diluting 
every 50.0 µL of the aforementioned SE working standard solutions with 950 µL of 
pooled blank mouse plasma.  SE plasma zero calibrator (0.000 ng mL-1) was prepared by 
diluting 50.0 µL of DMSO with 950 µL of pooled blank mouse plasma.  Aliquots (100.0 
µL) of plasma calibrators, QCs and dilution QC were kept in 1.50 mL microcentrifuge 
tubes (VWR, Radnor, PA, USA) and stored at -80°C before use.).   
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3.2.3 Preparation of plasma samples 
Plasma calibrators, QCs, dilution QC and the mouse plasma samples from animal 
study were thawed at room temperature.  Prior to the sample extraction by SALLE, the 
mouse plasma samples and dilution QC were subjected to 10-time dilution using pooled 
blank mouse plasma, then 5.00 μL of the working IS solution (1.20×103 ng mL-1) was 
added to each 100 L of plasma sample except the double blank where 5.00 μL of 
DMSO was added.  After vortex mixing, 600 μL of cold acetonitrile (-20 °C) and 100 μL 
of 2.00 M ammonium acetate were added sequentially to each plasma sample.  The 
resultant mixture was vortexed for 3 s, and then centrifuged at 15,000 × g and 4 °C for 10 
min.  After centrifugation, 200 µL aliquot of supernatant was diluted 1:1 with 10.0 mM 
ammonium acetate (pH 6.8) and used directly for LC–MS/MS analysis. 
3.2.4 LC-MS/MS system 
 The LC-MS/MS instrumentation used for this work consisted of a Shimadzu 
Prominence UFLC system (Shimadzu, Columbia, MD, USA) and an AB Sciex QTrap 
5500 mass spectrometer (AB Sciex, Foster City, CA, USA).  The UFLC system included 
a system controller (CBM-20A), two binary pumps (LC-20AD), a temperature-controlled 
autosampler (SIL 20AHT) and an online degasser (DGU20A3), and the mass spectrometer 
came with a Turbo IonSpray source.  The UFLC system outlet was connected to the mass 
spectrometer via high-pressure polyether ether ketone (PEEK) tubing (0.0625 in. o.d. x 
0.0100 in. i.d.).
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3.2.5 Chromatographic separation 
The chromatographic separation was carried out isocratically under ambient 
temperature on a reverse-phase Gemini Nx C18 (2.1 mm i.d x 150 mm, 5 μm, 110 Å) 
column (Phenomenex, Torrance, CA, USA) with an inline VHP filter (0.5 µm, stainless 
steel) from Upchurch Scientific (Oak Harbor, WA, USA).  The sample injection volume
was 10.0 µL and the mobile phase flow rate was 0.200 mL min-1. Prior to sample 
analysis, the column was first equilibrated with at least 20 column volumes of the mobile 
phase at a flow rate of 0.200 mL min-1.
3.2.6 Mass spectrometric detection 
 AB Sciex QTrap 5500 tandem mass spectrometer was operated in positive 
electrospray ionization (ESI+) mode.  It was tuned by flow injection analysis of SE (250 
ng mL-1) and norSE (500 ng mL-1) in the mobile phase for both compound-dependent and 
source-dependent parameters.  The optimized ionization parameters were as follows:
curtain (CUR), 20 psi; collision-activated dissociation (CAD) gas, medium; nebulizer gas
(GS1), 40 psi; turbo heater gas (GS2), 25 psi; ion spray voltage (IS), 5500V; source 
temperature (TEM), 300 °C.  High purity nitrogen (99.99%) was used as the nebulizer, 
auxiliary, collision and curtain gases.  The declustering potential (DP), entrance potential 
(EP), collision energy (CE) and collision cell exit potential (CXP) were set at 65, 6.0, 30 
and 8.0 V for SE and 80, 7.0, 35, 6.0 V for norSE.  Quantification was performed by 
multiple-reaction-monitoring (MRM) mode with mass transitions m/z 218.1 → 84.1 for 
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SE, and m/z 204.1 → 70.2 for norSE.  The dwell time for each transition was 300 ms and 
the mass resolutions (Q1 and Q3) were set at unit.
3.2.7 Data acquisition and analysis 
Data acquisition and peak integration were carried out by the AB Sciex Analyst® 
software (version 1.5.2).  The linear regression calibration equation was obtained by 
plotting the mean-peak-area ratios of SE plasma calibrators to those of the IS versus the 
concentrations of SE calibrators using a weighting factor of 1/x (where x is the nominal 
concentration of a plasma calibrator. 
3.2.8 Stability study 
The stability of SE was investigated using the SE stock solutions (2.00 mg mL-1), 
low and high plasma QC samples (1.80, 540 ng mL-1), and the stability of norSE was also 
determined separately using the norSE stock solution (1.20 mg mL-1) and a plasma 
sample at a concentration of 60.0 ng mL-1.  In the latter studies, SE was used as the IS for 
norSE. 
Stabilities of stock solution and mouse plasma samples were assessed by short-
term (6 and 24 h) standing on bench-top at 23°C and in the auto sampler at 4 °C (post 
preparative); freeze-and-thaw cycles; and long- term storage at -20 and -80 °C.  The 
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stabilities of SE and norSE were determined by comparing the mean-peak-area ratios of 
analyte to the IS in the test sample to those of freshly prepared samples, and expressed as 
percentages. 
3.2.9 Animal study 
The LC-MS/MS method developed was applied to the measurement of SE 
concentrations in the following animal study which had been approved by the Case 
Western Reserve University Institutional Animal Care and Use Committee (IACUC).   
BALB/c mice were obtained from Jackson laboratories (Bar Harbor, Maine, USA).  The 
mice were randomly housed, and had an average body weight of 25 g at the time of SE 
injections. The injectable SE (1 mg mL-1) was prepared in 10% DMSO aqueous solution 
which was given to mice as a single-bolus intraperitoneal (i.p.) injection at a dose of 4.00 
mg kg-1.  The mouse blood samples were collected via ocular puncture into 1.5 mL 
microcentrifuge tubes containing heparin as anti-coagulant at the following time points: 0 
(pre-dose), 1.5, 3, 7, 9, 15, 30 and 120 min.  For the pre-dose sample, the mouse was 
injected with only 10% DMSO aqueous solution without SE.  One whole blood sample 
(ca. 100 µL) was drawn from a single mouse at each time point, and was placed on ice 
immediately.  The whole blood samples were processed within 15 min of collection by 
centrifugation at 1000 x g and 4 °C for 10 min.  The harvested plasma samples (ca. 50 µL 
each) were stored at -80°C until analysis.  
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3.3 Results and discussion  
3.3.1 Method development  
3.3.1.1 Internal standard (IS) 
Due Structural analog of SE was used as IS since stable heavy isotope of SE was 
not available.  Initially, several custom-synthesized SE analogs were tested; however, 
most of the analogs chosen contained trace amount of SE due to the use of SE as 
precursor in synthetic routes.  NorSE was eventually chosen since it was free of SE.  
NorSE is structurally similar to SE (Figure 1), but differs only by one –CH2 unit, which 
has a pyrrolidinly instead of piperidinyl ring.   
3.3.1.2  Analyte solubility 
According to the Sci-Finder® Scholar database search, the log P values of SE and 
norSE are -0.969 and -1.497 respectively. These compounds should be hydrophilic rather 
than hydrophobic.  However, we found them to be difficult to dissolve either aqueous 
solution or plasma directly, which is probably attributed to their large rigid ring  
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Figure 1: Chemical structures of SE and the internal standard (IS).
(-)-Securinine (SE)
(monoisotopic mass = 217.1)
(+)-Norsecurinine (norSE)
(monoisotopic mass = 203.1)
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structures.  Although ethanol can dissolve these compounds, it can cause protein 
precipitation in plasma, resulting in poor analytical reproducibility.  The suitable solvent 
to dissolve both SE and norSE is DMSO. In this work, the SE and norSE working 
standard solutions were prepared in 100% DMSO, which was diluted to ≤10% DMSO in 
plasma calibrators and QC samples to ensure no protein precipitation from plasma 
matrices [20]. 
3.3.1.3 Mass spectrometric detection 
Due to the chemical structures of SE and norSE (IS), they are more readily to 
acquire protons than lose one in electrospray ionization. Hence, the positive electrospray 
ionization mode was used in this work.   
As shown in Figure 2A and 2C (full scan spectra), SE and norSE produced 
protonated molecular ions [M+H] + at m/z 218.1 and m/z 204, respectively.  These 
molecular ions produced major fragments at m/z 84.1 and m/z 70.2 (Figure 2B and 2D).  
Therefore, the mass transitions of m/z 218.1 → 84.2 for SE and m/z 204.1 → 70.2 for the 
IS were chosen for quantification. 
The assignment of the SE and norSE (IS) fragments was done by ACD/MS 
Fragmenter software (ACD Labs Toronto, Canada), and later confirmed by the 
experimental data. 
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Figure 2: The mass spectra of the precursor and product ions of SE and norSE (IS).  (A) the molecular ion of SE; (B) the 
major fragment of SE; (C) the molecular ion of norSE; and (D) the major fragment of norSE.
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3.3.1.4 Chromatographic separation  
In this work, reverse phase-liquid chromatography (RP-LC) columns such as 
Waters Xterra® RP-18 and Phenomnex Gemini Nx C18 (Phenomnex, Torrance, 
California) columns were tested for separation of SE and norSE.  Both columns were 
suitable for the separation of these compounds; however, Gemini Nx C18 was chosen for 
subsequent study because it gave higher signal intensity.
The composition of the mobile phase used for separation was first optimized.  
Acetonitrile was chosen as the organic solvent due to the greater solvent strength, and 
higher signal response in mass spectrometry than those of methanol; and ammonium 
acetate (10.0 mM) was used as the buffer salt because it suppressed the formation of 
sodium ion adducts and reduced peak tailing.  Since pH value of a mobile phase can 
influence the retention of analytes containing amine groups in RP-LC, the optimal pH 
value was also determined in this work.  The optimum separation of SE and norSE was 
obtained with ammonium acetate at pH 6.8.  Under this pH, SE (pKa = 8.29 ±0.20) and 
norSE (pKa = 8.78 ±0.20) were protonated and could be separated with baseline 
resolution.
The percent content of acetonitrile in the mobile phase was investigated.  Initially 
70% acetonitrile (ACN) was used; although it produced shorter retention times for the 
analytes it caused co-elution of endogenous lipids, and resulted in significant ion 
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suppression (Figure 3A).  It was identified by our experiment the lipid co-eluted was 1-
stearyl-rac-1glycerol (monoacylglycerol) [21].  To resolve this problem, the percent 
content of ACN was reduced to 40% where no apparent 1-stearyl-rac-1glycerol was 
observed (Figure 3B).
For this work, the optimized mobile phase composition consisted of 40% ACN 
and 60% 10 mM ammonium acetate, pH 6.8.  Using this mobile phase, separation of SE 
and norSE was achieved on the Gemini Nx C18 with retention times of 5.5 min and 2.6 
min for SE and norSE respectively (Figure 4).
3.3.1.5 Preparation of plasma samples  
In this work, liquid–liquid extraction (LLE) was first examined for sample 
preparation. In detail, 100 µL of plasma sample was first diluted with 0.05% ammonium 
aqueous solution to deprotonate the analytes, then 1.00 mL of ethyl acetate was added.  
The organic layer was transferred into borosilicate glass tubes (12 mm x 75 mm, VWR) 
and dried under nitrogen (10 psi) by TurboVap LV evaporator (Zymark, Hopkinton, 
Massachusetts, USA) at 40 °C for 30 minutes, and reconstituted in the mobile phase for 
analysis. Due to the high volatilities of SE and norSE, cross-vial contamination was 
observed.  Further the recoveries of analytes were low and the matrix effect was high by 
LLE.  To overcome these problems, a salting-out assisted liquid-liquid extraction 
(SALLE) protocol was later adopted for plasma sample preparation [22, 23], where a 
concentrated volatile salt (i.e., 2.00 M ammonium acetate) with a cold organic solvent  
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Figure 3: The effect of the percent organic additive in the mobile phase on the 
separation of SE from lipid interference.  (A) 70% ACN and 30% buffer (10 mM 
ammonium acetate pH 6.8) (B) 40% ACN and 60% buffer (10 mM ammonium 
acetate pH 6.8).  Top chromatograms shows the MRM mass transitions of SE, and 
the bottom chromatograms shows the MRM mass transitions of 1-Stearyl-rac-1-
glycerol (monoacyl glycerol). 
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(i.e., acetonitrile) were added to promote protein precipitation and induce phase 
separation.  The analytes extracted were determined by LC-MS/MS after a direct dilution 
of the organic phase with 10.0 mM ammonium acetate (pH 6.8) buffer (at 1:1 ratio).  The 
SALLE protocol was found to be effective in removal of matrix interference and 
producing good analyte recoveries (see data in sections 3.3.2.2 and 3.3.2.3). 
3.3.2 Method validation 
The method developed was validated in mouse plasma according to the US-FDA 
guidance for industry on bioanalytical method validation [17] and the subsequent 2006 
white paper of bioanalytical method validation workshop [18,19] in terms of selectivity, 
lower limit of quantitation (LLOQ), linear response range, recovery, matrix effect, 
accuracy and precision, as well as stability for both short-term sample processing and 
long-term sample storage. 
3.3.2.1 Selectivity and lower limit of detection (LLOQ) 
The selectivity of the method was evaluated by comparing the mass 
chromatograms of six lots of blank plasma samples with those of the spiked plasma 
calibrator at the LLOQ.  There were no endogenous interference observed at the retention 
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times and mass transitions of SE and the IS (Figure 4A).  Furthermore, there was no 
interference from the IS at the retention time and m/z of SE (Figure 4B).    
The LLOQ of the method was defined by lowest concentration on the calibration 
curve (0.600 ng mL-1) (Figure 4C).  As shown in TABLE I, the accuracy expressed as 
percent error (%RE) and precision as correlation of variation (%CV) were ≤ ±7% and ≤ 
5% respectively based on five replicates measurements in six lots of blank plasmas.  
Since the acceptable accuracy (%RE) and precision (%CV) were ≤ ± 20% and 20%, these 
results imply that the actual LLOQ of the method may be lower than 0.600 ng mL-1. 
3.3.2.2 Matrix effect  
Matrix effect was assessed by the matrix factor (MF), in six independent lots of 
mouse plasmas.  The absolute MF was determined by comparing the mean peak area of 
SE and IS in the spiked plasma matrix after SALLE (n = 5) with those of SE and IS in the 
mobile phase at low- and high- QC concentrations (1.80 and 540 ng mL-1).  The IS 
normalized MF was determined by MF of SE over those of the IS.  As shown in TABLE 
II, the absolute MFs of SE and IS ranged from 0.99-1.15 and 1.01-1.10 respectively.  The 
IS normalized MFs were in the range of 0.92-1.07.  These results indicate that the plasma 
matrix effect was negligible in this method. 
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Figure 4: The representative mass chromatograms of SE and the IS in mouse 
plasma: (A) double blank plasma (with neither SE nor IS); (B) single blank 
plasma (with IS only, 60 ng mL-1); and (C) at LLOQ (0.600 ng mL-1; IS, 60 ng 
mL-1).
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TABLE I: ACCURACY AND PRECISION OF SE AT LLOQ IN SIX DIFFERENT LOTS OF MOUSE 
PLASMA
Plasma 
matrix
Nominal 
[SE](ng mL-1)
Mean measured 
[SE](ng mL-1)  
SD(ng 
mL-1) %RE %CV
Lot 1 0.600 0.61 0.02 2 3
Lot 2 0.600 0.58 0.03 -3 5
Lot 3 0.600 0.57 0.01 -5 2
Lot 4 0.600 0.61 0.02 2 3
Lot 5 0.600 0.56 0.02 -7 4
Lot 6 0.600 0.56 0.03 -7 5
Each datum point calculated by five replicate measurements  
%RE =[(measured  − nominal )/(nominal )]×100% ; %CV = (SD/mean) x 100%.
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TABLE II:MATRIX EFFECT ON SE IN SIX INDIVIDUAL LOTS OF MOUSE PLASMA (N = 5) 
Plasma matrix [SE] (ng mL-1) MFSE ± SD
a MF
IS
± SDb IS Normalized 
MF ± SDc
Lot 1
1.80 1.03 ± 0.02 1.04 ± 0.04 0.98 ± 0.03
540 1.05 ± 0.05 1.09 ± 0.05 0.96 ± 0.03
Lot 2
1.80 1.02 ± 0.03 1.04 ± 0.02 0.98 ± 0.02
540 1.01 ± 0.05 1.10 ± 0.06 0.92 ± 0.04
Lot 3
1.80 1.03 ± 0.03 1.03 ± 0.04 0.99 ± 0.02
540 1.03 ± 0.03 1.03 ± 0.04 0.99 ± 0.02
Lot 4
1.80 1.05 ± 0.03 1.05 ± 0.03 1.01  ± 0.02
540 0.99 ± 0.06 1.06 ± 0.03 0.93  ± 0.07
Lot 5
1.80 1.01 ± 0.01 1.09 ± 0.02 0.92 ± 0.02
540 1.02 ± 0.01 1.01 ± 0.08 1.01 ± 0.09
Lot 6
1.80 1.15 ± 0.04 1.08 ± 0.02 1.07 ± 0.04
540 1.02 ± 0.01 1.02 ± 0.06 1.00 ± 0.05
a MFSE = (mean peak area of SE in extracted plasma matrix)/ (mean peak area of SE in mobile 
phase). 
b MFIS = (mean peak area of IS in extracted plasma matrix)/ (mean peak area of IS in mobile 
phase). 
c IS normalized MF = MFSE /MF IS. 
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3.3.2.3 Analyte recovery by SALLE 
The absolute recoveries were determined by comparing the mean peak area of SE 
and the IS in the corresponding QC plasma samples (n = 5) with those of SE and IS in the 
spiked plasma matrix after SALLE at low-, mid- and high- QC concentrations (1.80, 
18.0, 540 ng mL-1).  The IS normalized recoveries were determined by the recoveries of 
SE over those of the IS.  As shown in TABLE III, the mean absolute recoveries for SE 
and the IS ranged 79-86% and 79%- 80%, respectively; and the mean IS normalized 
recoveries ranged 99%-109%. 
3.3.2.4 Carryover 
The carryover of the analytes was assessed with five batches of validation 
calibrators by injecting plasma blank control immediately after the injection of the 
plasma calibrator at the highest concentration (600 ng mL-1).  There were no analytes 
peaks observed using 90% acetonitrile as the wash solvent.  Hence, sample carryover was 
not a problem in this method. 
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TABLE III: RECOVERY OF SE IN POOLED MOUSE PLASMA (N = 5) 
[SE] (ng mL-1)
Recovery
SE
± SD 
(%)
Recovery
IS
± SD 
(%)
IS Normalized Recovery 
± SD (%)
1.80 86 ± 3 79 ±  2 109 ± 2
18.0 84 ± 3 79 ± 1 107 ± 3
540 79 ± 2 80 ± 3 99 ± 2
PA = Mean peak area. 
Recovery of SE = (PA of SE in plasma matrix / PA of SE in extracted plasma matrix) x 100%. 
Recovery of IS = (PA of IS in plasma matrix / PA of IS in extracted plasma matrix) x 100%. 
IS normalized Recovery= (recovery of SE / recovery of the IS) x 100%. 
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3.3.2.5 Accuracy and precision 
The intra-run accuracy and precision were determined by five replicate 
measurements of each low-, mid- and high- QC samples (1.80, 18.0, 540 ng mL-1 ) as 
well as dilution QC 1.80 x 103 ng mL-1) in the same validation batch.  The inter-run 
accuracy and precision was determined by five parallel measurements of five identical 
sets of each QC samples over five different validation batches.  As shown in TABLE 
IV, the intra-run accuracy and precisions of all the QCs samples were ≤ ± 6% and ≤ 
5%, and the inter-run accuracy and precisions were ≤ ± 6% and ≤ 6% respectively.  
These results indicate that this method has adequate accuracy and precision. 
3.3.2.6 Linearity  
The calibration curves of SE in mouse plasma were constructed using a double 
blank (with neither SE nor IS), a single blank (zero calibrator, with IS) and seven non-
zero SE plasma calibrators (0.600, 1.20, 6.00, 12.0, 60.0,120 and 600 ng mL-1), with 
the concentration of the IS at 60.0 ng mL-1.  The mean peak area ratios of SE to IS 
were plotted against the nominal concentration of SE.  The calibration equation 
derived from five validation batches of calibrators using a 1/x weighted least-square 
linear regression was Y = 0.135 (± 0.009) x + 0.009 (± 0.008). A linear range of over  
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TABLE IV: INTRA- AND INTER-RUN ACCURACY AND PRECISION OF SE IN POOLED 
MOUSE PLASMA (N = 5) 
Intra-Runa
Nominal [SE] 
(ng mL-1)
Measured 
[SE] (ng mL-1) SD (ng mL
-1) %RE %CV
1.80 1.8 0.1 0.0 6
18.0 17.0 0.5 -6 3
540 545 6 1 1
1.80 x103
c
1.75 x10
3
8 x10
1
-3 5
Intra-Runb
Nominal [SE] 
(ng mL-1)
Measured 
[SE] (ng mL-1) SD (ng mL
-1) %RE %CV
1.80 1.7 0.1 -6 6
18.0 17.0 0.4 -6 2
540 549 8 2 1
1.80 x103
c
1.91 x10
3
7 x10
1
6 4
a Determined by five replicate measurements of each QC sample within a validation batch. 
b Determined by five parallel measurements of five identical QC samples at each concentration 
over five validation batches. 
c The dilution QC was measured after 10 times dilution with the pooled blank plasma.
113 
three orders of magnitude (0.600-600 ng mL-1) was obtained with a high correlation 
coefficient (r = 1.00) and the accuracy and precision of plasma calibrators were ≤ ±3 and 
≤ 6, respectively (TABLE V). 
3.3.2.7 Stability study 
The stabilities of SE and norSE under various storage conditions were tested.  As 
shown in TABLE VI,  the recoveries for SE stock solutions (23°C) at 6 and 24h time 
periods were 97-104% and at long term storage (-80°C, 5 months) it was 105%.  The 
recoveries for SE in mouse plasma at 6 and 24h time periods were 94-101% at the bench-
top (23°C), and 100-104% in the auto sampler (4°C).  The recoveries of 3 freeze-and-
thaw cycles (-20 to 23°C) and the long-term storage at -80°C (30 days) were 97-99% and 
97-99%, respectively.  However, the recovery of long term storage at -20°C (30 days) 
was low at 76-79%.  Therefore, -80°C should be used for long term storage and plasma 
sample analysis should be done within 24h timeframe.   
The recoveries of the IS under various conditions were in the range of 96-105%, 
indicating no significant loss was observed under the experimental conditions. 
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TABLE V: ACCURACY AND PRECISION OF SE PLASMA CALIBRATORS OVER FIVE 
VALIDATION BATCHES. 
Nominal [SE] 
(ng mL -1)
Measured [SE] 
(ng mL-1) SD (ng mL
-1) %RE %CV
0.600 0.59 0.02 -2 3
1.20 1.20 0.06 0.0 5
6.00 6.00 0.3 0.0 5
12.0 11.9 0.7 -1 6
60.0 62.0 4.0 3 6
120 120 5 0.0 4
600 597 7 -0.5 1
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TABLE VI: STABILITY OF SE AND IS IN MOUSE PLASMA SAMPLES UNDER VARIOUS 
CONDITIONS. 
Test conditions Temperature (° C) SEa
Recovery ± SD (%) (n = 3)
6 h 24 h
Bench-top 23 Stock solution 100 ± 1 103 ± 1
Freezer (5 months) -80 Stock solution 105 ± 2
Bench-top 23
Low QC 100 ± 2 96 ± 4
High QC 101 ± 5 94 ± 3
Autosampler 4
Low QC 100 ± 2 104 ± 7
High QC 100 ± 3 103 ± 3
3 Freeze-thaw cycles -20 to 23
Low QC 97 ± 2
High QC 99 ± 4
Long-term (30 days) -20
Low QC 76 ± 3
High QC 79 ± 3
Long-term (30 days) -80
Low QC 99 ± 3
High QC 97 ± 3
Test conditions Temperature (° C) NorSEb
Recovery ± SD (%) (n = 3)
6 h 24 h
Bench-top 23 Stock solution 104 ± 5 101 ± 5
Bench-top 23 Plasma sample 102 ± 6 103 ± 3
Autosampler 4 Plasma sample 101 ± 7 105 ± 4
3 Freeze-thaw cycles -20 to 23 Plasma sample 96 ± 5
a The concentration of SE stock solution was 2.00 mg mL-1 which was measured by serial dilution 
to1.80 ng mL-1 in mobile phase. The concentrations of SE in the low and high QCs were 1.80 and 
540 ng mL-1 respectively. The concentration of norSE stock solution was 1.20 mg mL-1 which 
was measured by serial dilution to 60.0 ng mL-1 in both the mobile phase and plasma sample. 
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3.3.3 Method application  
The validated LC-MS/MS method was applied to the measurement of plasma 
concentrations of SE in BALB/C mice.  The animal samples were collected and analyzed 
by the procedure described in the experimental section.  The representative mass 
chromatograms of SE in mouse plasma from the animal study are shown in Figure 5.  
The concentration of SE in each mouse sample was back calculated using the peak-area 
ratio of SE to that of the IS from the calibration equation with the proper dilution factor.  
Figure 6 shows the mean SE plasma concentration-time profile in mice (n = 3) after a 
single bolus i.p. injection of 4 mg kg -1 SE, which demonstrated the applicability of the 
method for pharmacokinetic study in mice. 
3.4 Conclusions  
An LC-MS/MS method for quantitative determination of securinine (SE) in 
mouse plasma has been developed and validated.  The method uses salting-out assisted 
liquid-liquid extraction (SALLE) procedure for sample preparation, reverse phase-liquid 
chromatography (RP-LC) for separation and tandem mass spectrometry for detection.   
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Figure 5: The representative mass chromatograms of animal study: (A) predosed 
mouse plasma (with IS, 60 ng mL-1); (B) plasma sample collected at 3 min after 
i.p. injection (with IS, 60 ng mL-1); and (C) plasma sample collected 30 min after 
i.p. injection (with IS, 60 ng mL-1). 
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Figure 6: The mean concentration-time profile of SE in mouse plasma (n = 3) 
after single i.p. bolus injection at the dose of 4 mg kg-1. 
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The method has good analyte selectivity, wide linear calibration range, and high 
accuracy and precisions, as well as the stability of routine analysis.  It has been applied to 
the measurement of SE in mouse plasma samples; therefore, maybe be useful for the 
pharmacological study of SE in mice. 
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CHAPTER IV 
DEVELOPMENT OF A STABLE ISOTOPE DILUTION LC-MS/MS METHOD 
FOR QUANTITATIVE DETERMINATION OF BISPHENOL A Β-D-
GLUCURONIDE IN HUMAN URINE  
4.1 Introduction 
Bisphenol A [2,2-bis(4-hydroxyphenyl]propane] (BPA) is an industrial chemical, 
that is widely used to make polycarbonate plastics and epoxy resins which are found in 
baby bottles, reusable water bottles, food containers as protective coatings, food and 
beverage cans as linings; and in dental composite fillings and sealants[1-3], among other 
applications.  The prevalent use of BPA-containing plastics in consumer products, 
frequently exposes humans to this compound via ingestion of trace amounts that leach 
into the food and beverages, as the BPA polymers are hydrolyzed at high temperature or 
under acidic/basic conditions [3-5]. 
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BPA is a synthetic estrogen, which mimics the endogenous female hormone 
action and interferes with the endocrine function [6, 7].  As a known endocrine-disrupting 
compound (EDC), the adverse physiological effects of BPA are subjects of ongoing 
clinical studies.  Nevertheless, BPA has been associated with altered behavior in children 
[8], whereas in adults; increased risk of diabetes [9] heart disease[9], obesity [10],  as 
well as, endocrine related dysfunctions i.e., disrupt thyroid hormone action [11, 12], 
block testosterone synthesis [13] and proliferation of human breast cancer cells [13, 14] 
cells and prostate cancer cells [15]etc.   
Therefore, in the recent years, studies have focused extensively on biological 
monitoring of BPA human exposure, potential toxicity and risk assessment by 
quantifying BPA concentrations in biological matrices [16, 17].  However, the 
measurement of BPA in biological samples often produces false results due to fact that 
BPA is readily available in laboratory environment and reagents [18, 19].  In humans, 
BPA is rapidly metabolized in the liver to bisphenol A β-D-glucuronide (BPA-G) and is 
eliminated via urine (Figure 1) [20-22].  Since BPA-G does not bind to estrogen receptor 
and does not exist in the environment without metabolism, it can therefore be used as a 
biomarker to assess human exposure to BPA.  Moreover, due to the rapid metabolism, the 
levels of urinary metabolites can be measured more precisely than those of the parent 
compound (i.e., BPA) and also the risk of sample contamination is reduced [23, 24]. 
The existing analytical methods for the measurement of BPA-G include: ELISA 
[25, 26], HPLC-FL [27], LC-ECD [26, 28], RIA [24] and LC-MS/MS [29-34]. However, 
there several limitations of this methods when analyzing biological samples, such as; 1) 
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Figure 1: BPA biotransformation in humans 
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use of solvent rather than blank urine as sample matrix for calibration [33]; 2) labor 
intensive sample preparation (i.e., solid phase extraction [30, 33, 35], enzymatic 
hydrolysis [31, 32] and chemical derivatization [34]; and 3) potential cross reactivity of 
the antibody with structurally related compounds [24, 25] which often result in bias 
results .
Therefore, in this work, a stable isotope dilution liquid chromatography tandem 
mass spectrometry (SID-LC-MS/MS) method has been developed. Deuterated BPA-G 
(d6-BPA-G) was used as a surrogate standard and carbon-13 labeled BPA-G (13C12-BPA-
G) as the internal standard (IS).  A liquid-liquid extraction procedure using phosphoric 
acid (15%) and ethyl acetate was developed for urine sample preparation. Isocratic 
separation of BPA-G, d6-BPA-G and the IS from urine matrix was achieved on a Waters 
X-select HSS T3 column (2.1 mm i.d x 100 mm, 2.5 μm) column with 17% acetonitrile 
and 83% 5.00 mM ammonium acetate, pH 7.3 at a flow rate of 0.580 mL min-1 in less 
than 6.5 min.  Quantification was carried out by negative electrospray tandem mass 
spectrometry (ESI-–MS/MS) in multiple-reaction monitoring mode (MRM).  The SID-
LC-MS/MS method developed has been validated according to the US Food and Drug 
Administration (USFDA) guidance for bioanalytical method validation [36-38] and 
applied to the measurement of BPA-G concentration in urine samples of 40 patients. 
4.2 Experimental 
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4.2.1 Chemicals and solutions  
Bisphenol A β-D-glucuronide (BPA-G, C21H24O8, MW, 404.41), Bisphenol A-
(rings-13C12) β-D-glucuronide (13C12-BPA-G, 13C12C9H24O8, MW, 416.32), creatinine, 
ammonium acetate (NH4Ac) and dimethyl sulfoxide (DMSO) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).  Bisphenol A-d6 β-D-Glucuronide (d6-BPA-G, 
C21H18 D6O8, MW 410.45) used as the internal standard (IS), was obtained from Toronto 
Research Chemicals (Toronto, Ontario, Canada).  Creatinine-N-methyl-D3 (d3-creatinine) 
was purchased from C/D/N Isotope Inc. (Pointe-Claire, Quebec, Canada) and HPLC-
grade acetonitrile was from Pharmco-AAPER (Shelbyville, KY, USA).  HPLC-grade 
water, ACS-grade o-phosphoric acid (85 wt. %), ACS-grade ammonium hydroxide (28-
30 w/w %) and ethyl acetate were purchased from Fisher Scientific (Pittsburg, PA, USA). 
The standard stock solutions of BPA-G, d6-BPA-G and 13C12-BPA-G were 
prepared in DMSO at a concentration of (100 µg mL-1) and aliquots (20.0 µL) of the 
stock solutions were stored at - 20°C prior to their use.  The standard working solutions 
of d6-BPA-G (0.00, 10.0, 20.0, 30.0, 100, 200, 600, 1.00×103, 2.00×103, 9.00×103, 
1.00×104 and 3.00×104 ng mL-1) were freshly prepared daily by serial dilution of the 
standard stock solutions with DMSO.  The working internal standard solution of 13C12-
BPA-G (400 ng mL-1) was prepared by serial dilution of the stock IS solution in DMSO.  
The stock solution of ammonium acetate (100 mM, pH 6.8) was prepared by 
dissolving appropriate amounts of buffer salt in a known volume of HPLC-water.  The 
working solution of ammonium acetate (5.00 mM, pH 7.3) was prepared by a 1/20 
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dilution of the 100 mM ammonium acetate with HPLC-water and the pH adjusted with 
ammonium hydroxide. The mobile phase for liquid chromatographic separation consisted 
of 17% acetonitrile and 83% 5.00 mM ammonium acetate, pH 7.3. 
4.2.2 Urine samples  
Human urine was obtained from several healthy donors at Cleveland State 
University. Samples were collected in sterile polypropylene containers and stored at -
20°C prior to analysis. Since BPA-G is endogenous, it’s difficult to obtain a real blank 
urine matrix; therefore, urine samples were first screened for background concentrations 
BPA-G.  Individual samples were analyzed by LC-MS/MS and the urine sample 
containing no detectable BPA-G was used as the blank urine matrix. Six lots of urine, 
assigned as lot A, B, C, D, E, and F were chosen from six different donors. Urine 
specimen from 20 newly diagnosed breast cancer patients were collected at University 
Hospitals Case Medical Center (UHCMC).  Samples were obtained from patients at a 
clinic visit prior to initiation of radiation therapy or chemotherapy. Control samples were 
collected from 20 women undergoing routine screening mammography at UHCMC 
whose mammograms were negative and had no prior history of cancer.  All specimens 
were collected in standard urine collection cups and were aliquoted the same day into 10 
mL BPA-free storage containers.  Specimens were then frozen at -80°C until analysis. 
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4.2.3 Preparation of urine calibrators and quality controls (QCs)  
d6-BPA-G urine calibrators (0.00, 0.500, 1.00, 5.00, 10.0,50.0,100, 500 ng mL-1) 
were prepared by diluting every 10.00 µL of the corresponding d6-BPA-G working 
standard solutions with 190.0 µL of blank urine in borosilicate glass tubes (13 mm x 100 
mm, Fisher Scientific). The d6-BPA-G urine QCs (1.50, 30.0 and 450 ng mL-1) and 
dilution QC (1.50 x 103 ng mL-1)   were prepared in the same manner as that of the urine 
calibrators. 200-µL aliquots of urine calibrators and QCs were kept at -20°C before use in 
capped borosilicate glass tubes.  
4.2.4 Sample preparation by liquid-liquid extraction (LLE) 
The urine samples (i.e., urine calibrators, QCs, dilution QC and patient samples) 
were thawed at room temperature unassisted. Prior to sample preparation by liquid-liquid 
extraction (LLE), the d6-BPA-G dilution QC samples (1.50 x 103 ng mL-1, 20 µL) were 
diluted by a factor of 10 with 180 µL blank urine. To each aliquot of 200.0 µL urine 
sample, 10.00 µL of the IS working solution (400 ng mL-1) was added except for the 
double blank where 10.00 μL of DMSO was added and vortex-mixed for 3 s using a 
VWR® Analog Multi-Tube Vortexer (VWR, Radnor, PA, USA).  The samples were 
acidified with 200 µL of 15% (v/v) phosphoric acid, vortex-mixed for 30 s and extracted 
with 2.00 mL of ethyl acetate.  After vortexing for 3 min, the mixture was centrifuged at 
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3800 x g for 10 min, then 1700 µL of the organic phase was transferred into a fresh 
borosilicate glass tube and dried under nitrogen (12 psi) in turbovap LV evaporator 
(Biotage, Charlotte, NC) at 40°C for 30 min.  The residue was reconstituted in 170 µL of 
solution containing 10% acetonitrile and 90% of 5.00 mM ammonium acetate (pH 7.3) 
before LC-MS/MS analysis.
4.2.5 Instrumentation  
The liquid chromatography tandem mass spectrometry (LC-MS/MS) system 
consisted of a Shimadzu Prominence UFLC system (Shimadzu, Columbia, MD, USA) 
equipped with a system controller (CBM-20A), two binary (LC-20AD) pumps, a 
temperature controlled (SIL 20AHT) autosampler, an online (DGU20A3) degasser, 
coupled to an AB Sciex QTRAP 5500 mass spectrometer (AB Sciex, Foster City, CA, 
USA) equipped with a Turbo IonSpray ESI source which was used for mass analysis and 
detection. The mass spectrometer was connected to the LC-system outlet via high-
pressure polyether ether ketone (PEEK) tubing (0.0625 in., o.d, x 0.0050 in., i.d)
designed for use in UPLC applications. During the first few minutes the effluent flow 
was diverted to waste to prevent contamination of the MS.
4.2.6 Liquid chromatography 
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The chromatographic separation was carried out at ambient temperature by 
isocratic elution using 17% acetonitrile and 83% 5.00 mM ammonium acetate, pH 7.3 at 
a flow rate of 0.580 mL min-1on a Water X-Select™ HSS T3 C18 (2.1 mm i.d x 100 mm,
2.5 μm,) column (Waters, Milford, MA, USA) preceded by a Water X-Select ™ HSS T3 
C18 (2.1 mm i.d x 5 mm, 2.5 μm,) Vanguard pre-column and an inert stainless steel in-
line filter (0.5 µm pore, 0.23 µL dead volume) from Upchurch Scientific (Oak Harbor,
WA, USA). The injection volume of each sample was 20.0 µL. Prior to sample analysis, 
the column was first equilibrated with the mobile phase using 20 times of the column 
volume.
4.2.7 Mass spectrometry 
The AB Sciex QTrap 5500 tandem mass spectrometer was operated in negative 
electrospray ionization (ESI-) mode.  It was tuned by flow injection of individual standard 
compounds (i.e., 500 ng mL-1 BPA-G, 500 ng mL-1 d6-BPA-G and 500 ng mL-1 IS) in the 
mobile phase for the ionization parameters.  The source-dependent ionization parameters 
were as follows: curtain (CUR), 20 psi; collision-activated dissociation (CAD) gas, 
medium; nebulizer gas (GS1), 70 psi; turbo heater gas (GS2), 65 psi; Turbo IonSpray 
voltage (IS), -3200 V; source temperature (TEM), 550°C.  High purity nitrogen was used 
as the nebulizer, auxiliary, collision and curtain gases.  The optimized compound-
dependent ionization parameters are summarized in TABLE I. Quantification was 
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TABLE I: MS/MS PARAMETERS 
MS/MS parameters BPA-G d6-BPA-G 13C12-BPA-G 
Q1 Mass (Da) 403.1 409.1 415.1
Q3 Mass (Da) 227.0 233.1 113.0
Source-Dependent parameters (V)
Declustering potential (DP) -100 -90 -90
Entrance potential (EP) -12 -12 -11
Collision energy (CE) -36 -38 -40
Collision cell exit potential (CXP) -15 -15 -18
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performed by multiple-reaction-monitoring (MRM) mode and the mass transitions of m/z 
403.1 → 227.1 for BPA-G, m/z 409.1 → 233.1 for d6-BPA-G and m/z 415.1 → 113.0 for 
the IS were monitored.  The dwell time for each transition was 533 ms and the instrument 
(Q1 and Q3) was operated in unit mass resolution.
4.2.8 Stability 
The stability study was performed on d6-BPA-G stock solution (100 µg mL-1) and 
in human urine using low and high QC samples (1.50, 450 ng mL-1) prepared as 
described in section 4.2.4 except the IS (20.0 ng mL-1) was added prior to sample 
preparation.  Short-term stabilities were assessed for 6h and 24h on the bench-top at 23°C 
, in the auto sampler (post preparative) at 4°C  and by three freeze and thaw cycles where 
the samples were frozen at -20°C and -80°C for at least 24h and thawed at 23°C (room 
temperature) unassisted.  Long- term stability was assessed for d6-BPA-G urine samples 
at -20°C and -80°C for 30 days. 
4.2.9 Application of the method 
The method developed was applied to the measurement of the BPA-G 
concentrations in 40 patients’ urine samples. Prior to analysis, the urine specimen were 
thawed at room temperature and 200.0 µL aliquots were placed in borosilicate glass 
134
tubes, capped and kept at -20°C along with the urine calibrators. The urine samples were 
thawed at room temperature and prepared along with urine calibrators (i.e., one double 
blank, one single blank and seven none-zero calibrators) and QCs at low-, med- and high-
concentrations (i.e., 1.50, 30.0 and 450 ng mL-1).  The samples were prepared by LLE as 
(section 4.2.4), and analyzed by the SID-LC-MS/MS method. The creatinine 
concentration of each patient urine sample was measured using LC-MS/MS method 
developed. 
4.2.10 Analysis of creatinine by LC-MS/MS 
The standard stock solutions (1mg mL-1) of creatinine and its deuterated IS (d3-
creatinine) were prepared by dissolving appropriate amounts of the compound in a known 
volume of HPLC-water. The stock solutions were stored at - 20°C prior to their use.  The 
standard working solutions of Creatinine (0.00, 10.0, 20.0, 30.0, 100, 200, 300, 1.00×103, 
2.00×103, 3.00×103, 1.00×104 ng mL-1) were freshly prepared daily by serial dilution of 
the standard stock solutions with HPLC-water.  The IS working solution (500 ng mL-1,
d3-creatinine) was prepared by serial dilution of the stock IS solution in HPLC-water. 
Creatinine standard calibrators (0.00, 0.500, 1.00, 5.00, 10.0, 50.0, 100 and 500 
ng mL-1) were prepared by diluting every 50.00 µL of the corresponding creatinine 
working standard solutions with 950.0 µL of the mobile phase in 1.50 mL 
microcentrifuge tubes (VWR, Radnor, PA, USA).   The creatinine solution QCs (1.50, 
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15.0 and 150 ng mL-1) were prepared in the same manner as that of the calibrators.  To 
each standard calibrator and QCs sample, 50 μL of IS working solution (500 ng mL-1, d3-
creatinine) was added and the samples were capped, vortex mixed for 30s and transferred 
into autosampler vial for LC-MS/MS analysis. 
The 40 patient urine samples were thawed at room temperature, vortex mixed and 
diluted 400 fold with the mobile phase. An aliquot (10uL) of each sample diluent was 
mixed with 990.0 µL of the mobile phase and 50 μL of the IS working solution (500 ng 
mL-1, d3-creatinine) in capped 1.5-mL microcentrifuge tubes.  The urine samples were 
vortex mixed for 30s and analyzed by LC-MS/MS along with creatinine standard 
calibrators and QCs samples. 
The AB Sciex QTrap 5500 tandem mass spectrometer was operated in positive 
electrospray ionization (ESI) mode.  It was tuned by flow injection analysis of 500 ng 
mL-1 creatinine and IS in the mobile phase for both the compound-dependent and the 
source-dependent parameters.  The optimized ionization parameters were as follows:
curtain (CUR), 25 psi; collision-activated dissociation (CAD) gas, medium; nebulizer gas  
(GS1), 65 psi; turbo heater gas (GS2), 65 psi; Turbo IonSpray voltage (IS), 3800V; 
source temperature (TEM), 550°C.  High purity nitrogen (99.99%) was used as the 
nebulizer, auxilliary, collision and curtain gases.  The declustering potential (DP), 
entrance potential (EP), collision energy (CE) and collision cell exit potential (CXP), 
were set at 40, 13.8, 27 and 18.0 V, and 50, 6.6, 28, 7.0 V for creatinine and the IS 
respectively.  Quantitative analysis was performed by multiple-reaction-monitoring
(MRM) mode with mass transitions m/z 114.0 → 44.1 for creatinine and m/z 117.0 → 
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47.1 for the IS.  The dwell time for each transition was 800 ms and the mass resolutions 
(Q1 and Q3) were set to unit.
The chromatographic separation  of creatinine and IS was achieved by isocratic 
elution on the Water X-Select™ HSS T3 C18 column with a mobile phase consisting of  
12% acetonitrile and 88% 10.00 mM ammonium acetate, pH 6.8 at a flow rate of 0.300 
mL min-1.  The injection volume of each sample (the standard or diluted samples) was 
10.0 µL and the column was maintained at ambient temperature. Prior to analysis, the 
column was first equilibrated with the mobile phase at a flow rate 0.3 mL min-1 with 20 
times the column volume. 
4.2.11 Data acquisition and analysis 
Data was acquired by the AB Sciex Analyst® software (version 1.6.1) and 
processed by the AB Sciex MultiQuant™ Software.  Quantitation of BPA-G was based 
on stable isotope ratio i.e., deuterated BPA-G (d6-BPA-G) was used as the calibration 
standard and carbon-13 labeled BPA-G (13C12-BPA-G) as the internal standard (IS).  The 
averaged peak area ratios of d6-BPA-G to the IS were plotted against the d6-BPA-G 
concentrations in urine calibrators for a linear regression equation using a weighting 
factor of 1/x (where x is the concentration of the calibrator).  The BPA-G concentration in 
a patient’s samples was calculated by the MultiQuant™ Software using the peak area 
ratio of d6-BPA-G to that of the IS and the calibration equation.  
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4.3 Results and discussion 
4.3.1 Method development 
4.3.1.1 Matrix and ideal isotope calibration  
Due to the widespread use of plastic in consumer products and food containers, 
BPA-G is readily detectable in human urine. Therefore, it’s difficult to acquire blank 
urine matrices for quantitative method development. The current analytical methods 
available use solvents (i.e., aqueous or organic ) rather than blank urine as sample matrix 
for calibration [33]; which is not a “true” calibration. A few of the methods report the use 
of one stable isotope as an internal standard (IS) i.e., BPAG-d6 [31], BPA-G-d14 and 
BPA-G-d16 [39] , where BPA-G is measured relative to the heavy isotope IS.  
In this work, two stable heavy isotope standards are used i.e., deuterated BPAG 
(d6-BPA-G) is used as the calibration standard and carbon-13 labled BPA-G (13C12-BPA-
G) is used as the internal standard (IS) for specific and accurate measurement of BPA-G 
in human urine. These stable heavy isotopes have the same physico-chemical properties 
as BPA-G but different molecular masses. Due to their low natural abundance, they are 
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not detectable in blank human urine, hence; solve the pre-existing problem of 
endogenous BPA-G in urine calibration matrices.     
4.3.1.2 Mass spectrometric detection 
Based on the chemical structures of BPA-G, d6-BPA-G and 13C12-BPA-G (IS) 
(Figure 2), these compounds are more readily to lose a proton than acquire one in 
electrospray ionization; therefore, the negative electrospray ionization mode was used in 
this work.  As shown in Figure 3A, 3C and 3E. BPA-G was deprotonated and produced a 
molecular ion [BPA-G-H] - at m/z 403.2, d6-BPA-G produced a molecular ion [d6-BPA-G 
-H] - at m/z 409.1 and the IS produced a molecular ion [IS-H] - at m/z 415.1.  These 
molecular ions were fragmented in the collision cell with high purity nitrogen gas, and 
resulted in the product ion spectra shown in Figure 3B, 3D and 3F).  
 The predominant product fragments for BPA-G, d6-BPA-G and the IS predicted 
by ACD/MS Fragmenter software (ACD Labs Toronto, Canada), and confirmed by the 
experimental data were m/z 227.0, m/z 233.1 and m/z 239.1 respectively.  However, 
interference was observed in the mass transitions of m/z 415.1 → 239.1 for the IS, 
therefore a different product ion for the IS was selected.   Hence, the mass transitions of 
m/z 403.1 → 227.0 for BPA-G , m/z 409.1 → 233.1 for BPA-G and m/z 415.1 → 113.0 
for the IS were chosen for quantification by multiple-reaction-monitoring (MRM) mode 
(Figure 4). 
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Figure 2: Chemical structures of BPA-G, d6-BPA-G and 13C12-BPA-G (IS). 
Bisphenol A β-D-glucuronide (BPA-G) 
 (monoisotopic mass = 404.1)
Bisphenol A-(rings-13C12) β-D-glucuronide
(13C12-BPA-G, Internal Standard)
(monoisotopic mass = 416.2)
Bisphenol A-d6 β-D-Glucuronide (d6-BPA-G) 
(monoisotopic mass = 410.2)
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Figure 3: The full scan mass spectra of BPA-G, d6-BPA-G and IS and their major product ions 
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Figure 4: The proposed major fragments of BPA-G, d6-BPA-G and IS 
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4.3.1.3 Chromatographic separation 
Separation of BPA-G, d6-BPA-G and IS was performed on reverse phase-liquid 
chromatography (RP-LC) columns (i.e., Waters Atlantis® T3 and Water X-Select ™ 
HSS T3 C18) suitable for polar compounds.  The Water X-Select ™ HSS T3 C18 was 
chosen for method development because it not only gave a higher signal intensity and 
better separation of the analytes from interfering urine components, but also symmetrical 
peak shapes without the need of adding ion pairing agents in the mobile phase. 
The composition of the mobile phase used for isocratic elution was optimized.  A 
significantly higher signal response and better peaks shapes where obtained with 
acetonitrile than with methanol, therefore acetonitrile was chosen as the organic solvent. 
The use of buffer salt was also evaluated and the addition of ammonium acetate (5.00 
mM) improved separation by decreasing the background signal; however, higher amounts 
of the salt were found to dramatically reduce the sensitivity.  The effect of the pH of the 
mobile phase on the analyte separation and detection was also investigated and ammonia 
was tested as an additive. While minimal improvement in the signal intensity of the 
analytes was obtained, a greater decrease in the background noise was achieved. In this 
work, optimal separation and detection of BPA-G, d6-BPA-G and IS was obtained with 
5.00 ammonium acetate at pH 7.3.  Under this pH the analytes were sufficiently 
deprotonated (glucuronide pKa = 3.1-3.2) and could be detected in ESI-–MS/MS. 
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4.3.1.4 Resolution of matrix interference 
The use of Water X-Select ™ HSS T3 C18 (2.1 mm i.d x 5 mm, 2.5 μm,) for 
separation and 75% actonitrile and 25% 5 mM ammonium acetate (pH 7.3) as mobile 
phase was first evaluated. Although shorter retention times were observed for BPA-G 
and d6-BPA-G, severe matrix interference was encountered in the urine matrix (Figure
5A).  The endogenous compounds co-eluted at the same retention time (tR) i.e., 3.5 min 
as the analytes and produced a similar product fragment of m/z 227.1 with BPA-G and 
m/z 233.1 with d6-BPA-G in tandem mass spectrometer. It was identified that the 
glucuronide conjugates of some isoflavones, (i.e., resveratrol) which are present in the 
human diet, have a molecular weight identical to BPA-G and similar lipophilicity (Figure 
6) and could possibly interfere with MS analysis of BPA-G. 
To minimize the matrix interference, different product ions for quantitation of 
BPA-G and d6-BPA-G were examined; however, this reduced the sensitivity of detection 
significantly and the interference was still observed. Therefore, separation was further 
optimized and the percent content of acetonitrile in the mobile phase was reduced to 
20%, where baseline resolution of BPA-G (tR = 8.7 min) and d6-BPA-G (tR =8.4 min) 
from the matrix interference was obtained (Figure 5B).  
Lastly, the RP-LC was further fine-tuned by varying the percent composition of 
the organic solvent (acetonitrile), along with other parameters such as flow rate, column 
temperature and the sample injection volume to achieve fast and efficient separation 
conditions. The optimal separation of the analytes was achieved under ambient 
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Figure 5: The effect of the organic percent additive in the mobile phase on the separation of BPA-G and d6-BPA-G from 
matrix interference. (A) 25% ACN 75% Buffer (5.00 mM ammonium acetate, pH 7.3) (B) 19.4 % ACN 80.6 % Buffer (5.00 
mM ammonium acetate, pH 7.3).  
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Figure 6: The logD comparison of BPA-G and resveratrol 
logD comparison
-5
-4
-3
-2
-1
0
1
2
0 1 2 3 4 5 6 7 8 9 10
pH
lo
gD
logD -BPAG
logD -Resveratrol
lo
gD
146
temperature on a Waters X-select HSS T3 column with retention times of 6.2 min for 
BPA-G, 6.1 min for d6-BPA-G and 6.2 min for the IS, using a mobile phase consisting of 
17% acetonitrile and 83% 5.00 mM ammonium acetate, pH 7.3 at a flow rate of 0.580 
mL min -1 with sample injection volume of 20.0 µL.  Under these conditions, the 
previously observed interference was completely separated and resolved from the 
analytes (Figure 7).  Therefore, during the first few minutes of SID-LC-MS/MS analysis, 
the effluent flow was diverted to waste to prevent contamination of the MS; hence the 
spike observed at tR=5.5 minutes is caused by switching the effluent flow from waste to 
the LC-MS/MS. 
4.3.1.5 Sample preparation by LLE 
In order to minimize the matrix interference due to the presence of co-eluting 
endogenous compounds in urine samples, two sample preparation techniques i.e., solid 
phase extraction (SPE) and liquid–liquid extraction (LLE) methods were evaluated.  
First, Strata X (C18) and Strata A-X (strong anion) SPE cartridges (Phenomenex, 
Torrance, California, USA) were tested. Although sufficient recoveries (>80%) were 
obtained on both cartridges, the recoveries were inconsistent and resulted in poor 
reproducibility.  Moreover, SPE method used did not completely eliminate the matrix 
interference observed.  Therefore, LLE using organic solvents i.e., methyl-t-butyl ether 
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Figure 7: The mass chromatograms (A) double blank-1 (BPA-G is readily detected) (B) double blank-2 (neither BPA-G, d6-
BPA-G nor IS detected) (C) single blank (IS only, 20 ng mL-1) (D) lowest urine calibrator (LLOQ, 0.500 ng mL-1). 
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(MTBE), ethyl acetate and MTBE: ethyl acetate (1:1) in combination with various acids 
(i.e., 4%, 10% and 15% phosphoric acid and 1M HCL) was investigated. Significant ion 
suppression was observed when MTBE was used; therefore, it was abandoned.  Urine 
samples acidified with 4% and 10% phosphoric acid, followed by extraction with ethyl 
acetate were found to have low recoveries whereas, those acidified with 1M HCL and 
15% phosphoric resulted in high extraction efficiencies.  In this work, ethyl acetate was 
chosen as the organic solvent for extraction in combination with 15% phosphoric acid 
due to the high signal response and low matrix interference, with matrix factors close to 
one (see section 4.3.2.2). 
4.3.1.6 Creatinine normalization 
Creatinine correction was performed to eliminate any effects of physiological 
urine dilution or concentration on patients’ samples. Creatinine is a breakdown product of 
creatinine phosphate, produced primarily in the muscle and excreted in urine. The rate of 
creatinine production is relatively constant, therefore, it’s used in urinary assays to 
normalize various metabolite concentrations [40, 41]. 
In this work, an LC-MS/MS method was developed to analyze creatinine in 
patients’ urine samples, because the commonly used methods (i.e., enzymatic and 
colorimetric assays) lack analytical selectivity.  Creatinine and d3-creatinine (IS) readily 
acquire a proton than lose one in electrospray ionization; therefore the positive mode was 
utilized in this work.  As shown in (Figure 8A and 8C) creatinine produced
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Figure 8: The full scan mass spectra of creatinine and IS and their major product 
ions. 
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a protonated molecular ion [Creatinine + H]+ at m/z 114.0 and IS (d3-creatinine) 
produced a  protonated molecular ion [IS + H]+ at m/z 117.0.  Fragmentation of these 
molecular ions produced a major product ion at m/z 44.1 for creatinine and m/z 47.1 for 
the IS (Figure 8B and 8D). The mass transitions chosen for quantification in multiple-
reaction-monitoring (MRM) were of m/z 114.0 → 44.1 and m/z 117.0 → 47.1 for the 
creatinine and IS respectively. Using a mobile phase of 12% acetonitrile and 88% 10.00 
mM ammonium acetate, pH 6.8, at a flow rate of 0.300 mL min-1, chromatographic 
separation of creatinine and the IS was achieved on a Waters X-select HSS T3 column 
(2.1 mm i.d x 100 mm, 2.5 μm) in less than 2 min (Figure 9).
To determine the creatinine concentration in patient samples, standard calibration 
curves of creatinine in the mobile phase were constructed using the ABSciex 
MultiQuant™ Software by plotting the mean peak area ratios of creatinine to the IS (d3-
creatinine) against the creatinine concentration in standard calibrators for a linear 
regression equation (Figure 10). The calibration equation obtained using a 1/x weighted 
least-square linear regression was Y = 0.0250 x + 0.029, r = 0.999).  A linearity of over 
three orders of magnitude i.e., 0.500 -500 ng mL-1 was obtained. The concentrations of 
creatinine in patient urine samples were back calculated with the peak area ratios of 
creatinine to those of the IS, using the calibration equation and dilution factor.  In this 
study the BPA-G concentration in patient samples were normalized by the amount of 
creatinine in each sample and reported as creatinine normalized BPA-G concentrations. 
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Figure 9: The mass chromatograms of A) creatinine standard calibrator (50 ng mL-1) and IS (25 ng mL-1) B) patient urine 
sample after dilution (1.56 mg mL-1 creatinine) and IS (25 ng mL-1).   
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Figure 10: Standard calibration curve for creatinine.
"Linear" Regression ("1 / x" weighting): y = 0.025 x + 0.0292 (r = 0.999)
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4.3.2 Method validation 
The method developed was validated in mouse plasma according to the US Food 
and Drug Administration (USFDA) guidelines [36-38] in terms of selectivity, lower limit 
of quantitation (LLOQ), linear response, recovery, matrix effect, accuracy, precision and 
stability for both short-term samples processing and long-term sample storage. 
4.3.2.1 Selectivity and lower limit of quantitation (LLOQ) 
 The selectivity of the method was evaluated by comparing the chromatograms of 
six different lots of urine samples with the corresponding d6-BPA-G spiked urine 
matrices. BPA-G is readily detected in blank human urine (Figure 7A). In this work, 
human urine containing no detectable BPA-G was used as the blank urine matrix, and no 
endogenous interferences from the urine matrix were observed in the double blank at the 
same retention time and m/z of BPA-G, d6-BPA-G and IS (Figure 7B). In addition, no 
interference or cross-talk from the 13C12-BPAG (IS) was observed in the urine matrix at 
the retention time and m/z of BPA-G and d6-BPA-G (Figure 7C). 
In this work, the LLOQ of the method was defined by lowest concentration on the 
calibration curve (0.500 ng mL-1) with a limit of accuracy and precision within ± 20% 
and 20% respectively (Figure 7D).   It was determined by analyzing five replicates of the 
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d6-BPA-G with IS at LLOQ in six sources of human urine matrices, independent of the 
urine calibrators.  The mean accuracy and mean precision of the method at LLOQ 
(TABLE II) were acceptable with ≤ ±12% of the relative error (RE) and ≤ 6% of the 
coefficient of variation (CV).   
4.3.2.2 Matrix effect  
 The matrix effect was assessed by the matrix factor (MF). The absolute MF was 
determined in low- , med -  and high- QC controls (1.50, 30.0 and 450 ng mL-1) by 
comparing the peak area ratios of d6-BPA-G to the IS in the spiked urine matrix after 
LLE (n = 5)  with those prepared in the mobile phase.  The IS normalized MF was 
determined by MF of d6-BPA-G over the MF of the IS.  As shown in TABLE III, the 
absolute MFs of d6-BPA-G and IS ranged from 0.95-1.03 and 0.96-0.97 respectively.  
The IS normalized MFs were in the range of 0.98-1.06.  These results revealed that the 
urine matrix effect was in the magnitude of -2% to 6% (<± 15%), hence it was not 
significant and could be neglected. 
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TABLE II:ACCURACY AND PRECISION OF D6-BPA-G AT LLOQ IN SIX DIFFERENT LOTS OF 
HUMAN URINE
Urine 
matrix
Nominal 
[d6-BPA-G ] 
(ng mL-1)
Mean measured 
[d6-BPA-G] 
(ng mL-1)
SD
(ng mL-1)
%RE %CV
Lot A 0.500 0.52 0.09 4 2
Lot B 0.500 0.47 0.03 -6 4
Lot C 0.500 0.44 0.01 -12 1
Lot D 0.500 0.45 0.04 -10 6
Lot E 0.500 0.47 0.01 -6 2
Lot F 0.500 0.47 0.01 -6 1
Each datum point calculated by five replicate measurements  
%RE = [measured − nominal / nominal] ×100%; %CV = (SD/mean) x 100%.
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TABLE III: MATRIX EFFECT OF D6-BPA-G IN SIX INDIVIDUAL LOTS OF HUMAN URINE (N 
= 5) 
[d6-BPA-G]
(ng mL-1)
MF
d6-BPA-G
 ± SDa MF
IS
± SDb IS Normalized MF ± SD
1.50 0.95 ± 0.04 0.96 ± 0.01 0.98 ± 0.04
30.0 0.99 ± 0.01 0.96 ± 0.02 1.03 ± 0.02
450 1.03 ± 0.01 0.97 ± 0.03 1.06 ± 0.02
PA = Mean peak area. 
a MFd6-BPA-G = (PA of d6-BPA-G in extracted urine matrix)/ (PA of d6-BPA-G in mobile phase). 
b MFIS = (PA of IS in extracted urine matrix)/ (PA of IS in mobile phase). 
c IS normalized MF = MFd6-BPA-G /MF IS. 
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4.3.2.3 Recovery 
The absolute recovery of LLE was determined in low-, mid- and high- QC 
controls (1.50, 30.0, 450 ng mL-1) by comparing the mean peak area of d6-BPA-G and IS 
in the corresponding QC urine samples (n=5) with those of d6-BPA-G and IS in the 
spiked in urine matrix after LLE.  The IS normalized recovery was determined by the 
recovery of d6-BPA-G over the recovery of the IS.  TABLE IV shows the mean absolute 
recoveries for d6-BPA-G ranged from 101-103% and 104% - 107% for the IS and the 
mean IS normalized recoveries obtained were 97%. 
4.3.2.4 Carry over 
Carry-over was assessed in each validation batch of calibrators by analysis of the 
standard calibrator with the highest concentration (500ng mL-1) followed by an extracted 
blank urine sample.  In this assay, no peak was observed in the plasma double blank at 
the retention time of BPA-G or d6-BPA-G using 90% acetonitrile as the wash solvent.  
Hence no carry-over was observed in this work.  
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TABLE IV: RECOVERY OF D6-BPA-G IN URINE MATRIX (N = 5) 
[d6-BPA-G] 
(ng mL-1)
Recovery
d6-BPA-G
 ± 
SD (%)
Recovery
IS
± 
SD (%)
IS Normalized Recovery ± 
SD (%)
1.50 102 ± 2 105 ± 3 97 ± 4
30.0 101 ± 2 104 ± 1 97 ± 2
450 103 ± 1 107 ± 2 97 ± 2
PA = Mean peak area. 
Recovery of d6-BPA-G = (PA of d6-BPA-G in urine matrix / PA of d6-BPA-G in extracted urine 
matrix) x 100%. 
Recovery of IS = (PA of IS in urine matrix / PA of IS in extracted urine matrix) x 100%. 
IS normalized Recovery= (recovery of d6-BPA-G / recovery of the IS) x 100%. 
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4.3.2.5 Accuracy and precision 
The intra-run accuracy and precision were determined by five replicate 
measurements of each low-, mid- and high- QC samples (1.50, 30.0, 450 ng mL-1 ) as 
well as dilution QC 1.50 x 103 ng mL-1) in the same validation batch.  The accuracy was 
expressed as percent relative error (%RE) and the precision expressed as coefficient 
variation (% CV).  The inter-run accuracy and precision was determined by five parallel 
measurements of five identical sets of each QC samples in five different validation 
batches.  As shown in TABLE V the intra-run accuracy and precisions of all the QCs 
samples were ≤ ± 7% and ≤ 3% and the inter-run accuracy and precisions were ≤ ± 10% 
and ≤ 4% respectively.  These results indicate that this method has adequate 
reproducibility and accuracy.  
4.3.2.6 Linearity   
The calibration curves of d6-BPA-G in urine were constructed using a double 
blank (with neither BPA-G, d6-BPA-G nor IS), a single blank (zero calibrator, with IS 
only) and seven non-zero d6-BPA-G urine calibrators (0.00, 0.500, 1.00, 5.00, 10.0, 
50.0,100, and 500 ng mL-1) with the concentration of the IS at 10.0 ng mL-1.  The mean 
peak area ratios of d6-BPA-G to the IS were plotted against the nominal concentration of 
d6-BPA-G in urine.  The calibration equation derived from five batches of calibration  
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TABLE V:INTRA- AND INTER-RUN ACCURACY AND PRECISION OF D6-BPA-G IN POOLED 
HUMAN URINE (N = 5) 
Intra-Runa
Nominal [d6-BPA-G] 
(ng mL-1)
Measured [d6-BPA-G] 
(ng mL-1) SD (ng mL
-1) %RE %CV
1.50 1.47 0.06 -2 3
30.0 32.1 0.7 7 2
450 481 7 7 2
1.50 x103
c
1.44 x103 1.0 x101 -4 1
Intra-Runb
Nominal [d6-BPA-G] 
(ng mL-1)
Measured [d6-BPA-G] 
(ng mL-1) SD (ng mL
-1) %RE %CV
1.50 1.39 0.06 -8 4
30.0 29.6 0.5 -1 2
450 409 2 -9 1
1.50 x103
c
1.35 x103 1.0 x101 -10 1
a Determined by five replicate measurements of each QC sample within a validation batch. 
b Determined by five parallel measurements of five identical QC samples at each concentration 
over five validation batches.  
c The dilution QC was measured by a 10 times dilution. 
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curves using a 1/x weighted least-square linear regression was Y = 0.0652 (±0.0028) x + 
0.0282(±0.0097), r = 9997 (±0.0004).  A linearity of over three orders of magnitude 
(0.500-500 ng mL-1) was obtained in urine with high correlation coefficient.  The 
accuracy and precision of d6-BPA-G urine calibrators were ≤ ± 12 and ≤ 13 respectively 
(TABLE VI). 
4.3.2.7 Stability study 
The short term stability of d6-BPA-G in human urine was tested under various 
storage conditions and was determined by comparing the mean peak-area ratios of d6-
BPA-G to the IS in the test sample to those of freshly prepared samples and expressed as 
a percent recovery. 
As shown in TABLE VII, the recoveries for BPA-G stock solutions (23°C) at 6 
and 24h time period were 95-98%. The recoveries for BPA-G in urine at 6 and 24h time 
period were 97-101% and 98-104%, for the bench-top (23°C) and the auto sampler (4°C) 
conditions respectively.  The three freeze-and-thaw cycles (-20 to 23°C and -80 to 23°C) 
were in the range of 93-104%. The recovery at long term storage (-20°C and -80°C, 30 
days) were 98-101%.  These studies indicate that d6-BPA-G is stable under the 
experimental conditions tested and so is BPA-G, since no significant loss or degradation 
was observed. 
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TABLE VI: ACCURACY AND PRECISION OF D6-BPA-G URINE CALIBRATORS OVER FIVE 
VALIDATION BATCHES. 
Nominal [d6-BPA-G] 
(ng mL -1)
Measured [d6-BPA-G] 
(ng mL-1) SD (ng mL
-1) %RE %CV
0.500 0.560 0.120 12 13
1.00 1.1 0.1 10 5
5.00 5.2 0.4 5 8
10.0 10.5 0.6 5 5
50.0 51.0 2.0 2 4
100 102 3 2 3
500 490 19 -2 4
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TABLE VII: STABILITY OF D6-BPA-G IN HUMAN URINE SAMPLES UNDER VARIOUS 
CONDITIONS. 
Test conditions Temperature (° C) d6-BPA-G
a
Recovery ± SD (%) (n = 3)
6 h 24 h
Bench-top 23 Stock solution 98 ± 2 95 ± 3
Bench-top 23
Low QC 99 ± 4 97 ± 1
High QC 104 ± 2 104 ± 1
Autosampler 4
Low QC 98 ± 3 99 ± 1
High QC 104 ± 2 104 ± 1
3 Freeze-thaw cycles -20 to 23
Low QC 93 ± 4
High QC 104 ± 2
3 Freeze-thaw cycles -80 to 23
Low QC 96 ± 3
High QC 101 ± 1
Long-term (30 days) -20
Low QC 100 ± 1
High QC 98 ± 1
Long-term (30 days) -80 
Low QC 101 ± 1
High QC 99 ± 2
a The concentration of d6-BPA-G stock solution was 100 µg mL-1 which was measured by serial 
dilution  to1.50 ng mL-1 in mobile phase. The concentrations of d6-BPA-G in the low and high 
QCs were 1.50 and 450 ng mL-1 respectively. 
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4.3.2.8 Method application  
The applicability of the validated stable isotope dilution LC-MS/MS method was 
demonstrated by analysis of BPA-G concentrations in 40 patients’ samples to assess 
variability within this patient population. Prior to analysis, the patients’ urine samples 
were thawed at room temperature.  The urine samples, along with urine calibrators and 
QCs were prepared by the procedure mentioned in section 4.2.4, and analyzed by the LC-
MS/MS method developed. The concentrations of d6-BPA-G in patients’ urine samples 
were back calculated with the peak area ratios of d6-BPA-G to those of the IS using the 
calibration equation. Figure 11 shows examples of SID-LC-MS/MS mass chromatograms 
corresponding to patients’ urine samples with no BPA-G detected (Figure 11A) and with 
12.2 g mL-1 BPA-G detected (Figure 11B).  
The concentrations of creatinine in patient urine samples were determined by the 
LC-MS/MS method developed (see section 4.2.10) and the BPA-G measured from each 
patient’s sample was normalized by the amount of creatinine in each sample.  The BPA-
G concentrations in patient samples were reported as µg g-1 of creatinine (i.e., creatinine 
normalized BPA-G concentrations).  BPA-G was detected and quantified in 65% (n 
=13/20) of the analyzed samples with creatinine-normalized BPA-G concentrations 
ranging from ND (not detected) to 7.82 µg g-1 of creatinine (TABLE VIII).  This method 
is useful for the evaluation and assessment of human exposure to BPA. 
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Figure 11: Mass chromatogram of patients (A) P1 urine sample, with neither 
BPA-G nor d6-BPA-G detected and IS (20 ng mL-1) (B) P10 urine sample with 
12.2 ng mL-1 BPA-G detected, no d6-BPA-G detected and IS (20 ng mL-1). 
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TABLE VIII: CONCENTRATION OF BPA-G IN 40 PATIENTS’ URINE  SAMPLES
Patient # SampleID
Measured 
[BPA-G]
(ng mL-1)
Measured 
[Creatinine]
(mg mL-1)
Creatinine-Corrected
[BPA-G]µg g-1 
Creatinine
P1 2155 ND 0.597 ND
P2 2156 0.534 0.968 0.552
P3 2162 ND 0.194 ND
P4 2165 ND 1.40 ND
P5 2171 6.07 2.85 2.13
P6 2178 1.56 1.79 0.870
P7 2179 ND 0.889 ND
P8 2180 ND 0.861 ND
P9 2181 1.02 1.72 0.592
P10 2182 12.2 1.56 7.82
P11 2187 2.03 1.33 1.53
P12 2186 0.815 2.08 0.391
P13 4000 5.57 0.972 5.73
P14 4037 ND 0.565 ND
P15 4041 4.97 2.45 2.03
P16 4079 4.76 3.12 1.52
P17 4088 2.02 2.16 0.934
P18 4090 ND 0.682 ND
P19 4091 1.63 0.789 2.06
P20 4093 5.44 1.32 4.13
P21 3939 0.531 1.73 0.307
P22 3924 5.25 3.33 1.58
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P23 3906 ND 2.52 ND
P24 3904 ND 0.707 ND
P25 3900 1.01 1.56 0.652
P26 3899 0.972 0.477 2.04
P27 3898 2.84 1.83 1.55
P28 3895 0.616 1.95 0.316
P29 4042 ND 0.190 ND
P30 4027 0.728 0.817 0.891
P31 4019 ND 2.50 ND
P32 4003 ND 0.867 ND
P33 3999 0.677 1.04 0.654
P34 3996 ND 0.807 ND
P35 3976 0.962 0.837 1.15
P36 3968 1.05 0.886 1.18
P37 3957 ND 1.24 ND
P38 4135 ND 3.04 ND
P39 4131 ND 1.04 ND
P40 4125 ND 0.0634 ND
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4.4 Conclusions  
A stable isotope dilution LC-MS/MS method for specific and accurate 
quantitative measurement of BPA-G in human urine has been developed and validated.  
The method uses deuterated BPA-G (d6-BPA-G) as the calibration standard and carbon-
13 labeled BPA-G (13C12-BPA-G) as the internal standard (IS).  A simple liquid-liquid 
extraction protocol was used for efficient urine samples preparation, reverse phase-liquid 
chromatography (RP-LC) for separation and tandem mass spectrometry for detection.  
The method has high analyte selectivity and sensitivity with an LLOQ of 0.500 ng mL-1
in urine matrix. It has good accuracy and precisions as well as the stability of routine 
analysis.  This method was successfully applied to the measurement of BPA-G 
concentrations in urine samples of 40 patients and may be useful in biomonitoring and 
toxic kinetics studies of BPA. 
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